10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

0001193125-16-765892.txt : 20161110 0001193125-16-765892.hdr.sgml : 20161110 20161110161001 ACCESSION NUMBER: 0001193125-16-765892 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161110 DATE AS OF CHANGE: 20161110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNLINK HEALTH SYSTEMS INC CENTRAL INDEX KEY: 0000096793 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 310621189 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12607 FILM NUMBER: 161988137 BUSINESS ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 7709337000 MAIL ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 FORMER COMPANY: FORMER CONFORMED NAME: KRUG INTERNATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TECHNOLOGY INC DATE OF NAME CHANGE: 19860803 FORMER COMPANY: FORMER CONFORMED NAME: COMANCO INDUSTRIES INC DATE OF NAME CHANGE: 19710719 10-Q 1 d215332d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-12607

SUNLINK HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Ohio

31-0621189

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

900 Circle 75 Parkway, Suite 1120, Atlanta, Georgia 30339

(Address of principal executive offices)

(Zip Code)

(770) 933-7000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter during the preceding 12 months (of for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of Common Shares, without par value, outstanding as of November 10, 2016 was 9,443,408.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)


	September 30,
	2016			June 30,
	(unaudited)			2016
ASSETS
Current Assets:
Cash and cash equivalents	$	12,801		$	3,261
Receivables - net		5,906			6,166
Inventory		2,323			2,612
Deferred income tax asset		0			624
Current assets held for sale		0			2,461
Prepaid expense and other assets		3,008			2,768

Total current assets		24,038			17,892

Property, plant and equipment, at cost		31,378			33,914
Less accumulated depreciation		20,686			20,920

Property, plant and equipment - net		10,692			12,994
Noncurrent Assets:
Intangible assets - net		2,660			2,695
Goodwill		461			461
Deferred income tax asset		0			1,698
Noncurrent assets held for sale		2,136			7,633
Other noncurrent assets		676			732

Total noncurrent assets		5,933			13,219

TOTAL ASSETS	$	40,663		$	44,105

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	2,160		$	3,391
Current maturities of long-term debt		7,113			7,473
Accrued payroll and related taxes		2,347			2,872
Due to third party payors		1,042			1,883
Income tax payable		81			2
Current liabilities held for sale		0			2,745
Other accrued expenses		1,621			1,685

Total current liabilities		14,364			20,051
Long-Term Liabilities
Long-term debt		1,710			2,979
Deferred income tax liability		378			0
Noncurrent liability for professional liability risks		1,131			1,161
Other noncurrent liabilities		519			425

Total long-term liabilities		3,738			4,565
Commitment and Contingencies
Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares		0			0
Common Shares, without par value:
Issued and outstanding, 9,444 shares at September 30, 2016 and at June 30, 2016		4,722			4,722
Additional paid-in capital		13,588			13,539
Retained earnings		4,671			1,648
Accumulated other comprehensive loss		(420	)		(420	)

Total Shareholders’ Equity		22,561			19,489

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	40,663		$	44,105

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE EARNINGS (LOSS)

(In thousands, except per share amounts)

(unaudited)


	Three Months Ended
	September 30,
	2016			2015
Operating revenues (net of contractual allowances)	$	13,079		$	17,300
Less provision for bad debts of Healthcare Facilities Segment		33			716

Net revenues		13,046			16,584
Costs and Expenses
Cost of goods sold		4,636			4,597
Salaries, wages and benefits		5,845			8,317
Provision for bad debts of Specialty Pharmacy Segment		91			222
Supplies		436			916
Purchased services		708			869
Other operating expenses		1,710			2,201
Rent and lease expense		129			201
Depreciation and amortization		444			427

Operating Loss		(953	)		(1,166	)
Other Income, (Expense):
Gain on sale of assets		22			1
Gain on extinguishment of debt		46			0
Interest expense - net		(221	)		(217	)

Loss from Continuing Operations before income taxes		(1,106	)		(1,382	)
Income Tax Expense (Benefit)		144			(249	)

Loss from Continuing Operations		(1,250	)		(1,133	)
Earnings from Discontinued Operations, net of tax		4,273			(535	)

Net Earnings (Loss)		3,023			(1,668	)
Other comprehensive income		0			0

Comprehensive Earnings (Loss)	$	3,023		$	(1,668	)

Earnings (Loss) Per Share:
Continuing Operations:
Basic	$	(0.13	)	$	(0.12	)

Diluted	$	(0.13	)	$	(0.12	)

Discontinued Operations:
Basic	$	0.45		$	(0.06	)

Diluted	$	0.45		$	(0.06	)

Net Earnings (Loss):
Basic	$	0.32		$	(0.18	)

Diluted	$	0.32		$	(0.18	)

Weighted-Average Common Shares Outstanding:
Basic		9,443			9,443

Diluted		9,443			9,443

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Three Months Ended
	September 30,
	2016			2015

Net Cash Used in Operating Activities	$	(3,190	)	$	(815	)

Cash Flows from Investing Activities:

Proceeds from sale of Chestatee		14,620			0
Expenditures for property, plant and equipment - continuing operations		(244	)		(463	)
Expenditures for property, plant and equipment - discontinued operations		0			(15	)


Net Cash Provided by (Used in) Investing Activities		14,376			(478	)

Cash Flows from Financing Activities:
Payments on long-term debt - continuing operation		(1,646	)		(175	)
Payments on long-term debt - discontinued operations		0			0


Net Cash Used in Financing Activities		(1,646	)		(175	)


Net increase (decrease) in Cash and Cash Equivalents		9,540			(1,468	)

Cash and Cash Equivalents Beginning of Period		3,261			5,974


Cash and Cash Equivalents End of Period	$	12,801		$	4,506


Supplement Disclosure of Cash Flow Information:

Cash Paid (Received) for:
Interest	$	206		$	200

Income taxes	$	33		$	76

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE MONTHS ENDED SEPTEMBER 30, 2016

(all dollar amounts in thousands except per share amounts)

(unaudited)

Note 1. –Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of September 30, 2016 and for the three month periods ended September 30, 2016 and 2015 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2016 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2016, filed with the SEC on September 30, 2016. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three month period ended September 30, 2016 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Note 2. – Business Operations

Business Operations

SunLink owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:

•

The Healthcare Facilities Segments, which is composed of:

•

A subsidiary which owns and operates an 84-licensed-bed, acute care hospital, which includes an 18-bed GPU, and a 66-bed nursing home.

•

A subsidiary which owns and operates a 100-bed nursing home. This subsidiary also owns a hospital building and leases the portion of that building occupied by the emergency department to an unaffiliated healthcare provider.

•

Two separate subsidiaries which own medical buildings, which are leased to unaffiliated healthcare providers.

•

A subsidiary which owns a closed hospital building and a medical office building which it currently rents office space to one unaffiliated healthcare provider.

•

The Specialty Pharmacy Segment, which is composed of four operational areas:

•

Retail pharmacy products and services, all of which are conducted in rural markets;

•

Institutional pharmacy services;

•

Specialty pharmacy services; and

•

Durable medical equipment.

Our Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary.

The business strategy of SunLink is to focus its efforts on improving internal operations of the existing pharmacy business and healthcare facilities subsidiaries and on the sale or disposition of its subsidiaries’ underperforming assets. The Company considers the disposition of facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments and competition from existing and potential competitors, capital improvement needs, prevailing reimbursement rates for drugs and medical services under various Federal and state programs (e.g., Medicare and Medicaid) and by private payors, corporate strategy and other corporate objectives. The Company also is considering potential upgrades and improvements to certain of its healthcare facilities. The Company believes its Healthcare Facilities Segment and its Pharmacy Segment continues to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its specialty pharmacy business. The Company also has an agreement, subject to various conditions, to sell a medical office building. The Company has used cash proceeds from recent dispositions of assets to pay off certain liabilities and may use a portion of its existing cash assets, as well as any net proceeds from future dispositions, to prepay long-term debt, return capital to shareholders via a repurchase of shares or a dividend, make improvements to existing facilities, and for other general corporate purposes. There can be no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.

Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that the publicly traded Company or any particular subsidiary of the Company owns or operates any asset, business or property. The Trace Hospital, pharmacy operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc.

Note 3. – Discontinued Operations

All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended
	September 30,
	2016			2015
Net Revenues:
Chestatee Hospital	$	2,101		$	3,888
Other Sold Hospitals		(234	)		100

	$	1,867		$	3,988

Earnings (loss) before income taxes:
Chestatee Hospital	$	(64	)	$	(594	)
Other Sold Hospitals		(238	)		(188	)
Life sciences and engineering		(37	)		(36	)

Earnings (loss) before income taxes		(339	)		(818	)

Gain on Sale:
Chestatee Hospital		7,246			0

Earnings (Loss) before income taxes		7,246			(818	)


Income tax expense (benefit)		2,634			283


Earnings (Loss) from discontinued operations	$	4,273		$	(535	)

Chestatee Hospital—On August 19, 2016, the Company’s subsidiary Southern Health Corporation of Dahlonega, Inc. (“Chestatee”) sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,246 is subject to adjustment for various purchase price adjustments. Chestatee retained certain liabilities, including for employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds have been used for the payment of debt. The assets sold and liabilities assumed are shown as assets held for sale in our consolidated balances as of June 30, 2016.

Other Sold Hospitals – Subsidiaries of the Company have sold substantially all of the assets of three hospitals (“Other Sold Hospitals”) during the period July 2, 2012 to December 31, 2014. Certain assets and liabilities were retained in these sales and the results of the retained assets and liabilities are classified as discontinued operations in our condensed consolidated financial statements for the three month periods ended September 30, 2016 and 2015. The loss before income taxes of the Other Sold Hospitals results primarily from negative prior year Medicare and Medicare cost report settlements.

Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three months ended September 30, 2016 and 2015.

The components of pension expense for the three months ended September 30, 2016 and 2015, respectively, were as follows:


	Three Months Ended
	September 30,
	2016			2015
Interest Cost	$	13		$	16
Expected return on assets		(8	)		(8	)
Amortization of prior service cost		32			28

Net pension expense	$	37		$	36

SunLink contributed $35 to the plan in the three months ended September 30, 2016 and expects to contribute an additional $105 during the last three quarter of the fiscal year ending June 30, 2017.

Note 4. – Assets held for sale

On November 7, 2016, the Company’s subsidiary SunLink Healthcare Professional Property, LLC entered into an agreement to sell a medical office building in Ellijay, Georgia for approximately $4,900. The sale is subject to a number conditions, including buyer due diligence and is expected to close by December 31, 2016. The net assets to be sold of $2,136 have been reclassified as Assets Held for Sale in the September 30, 2016 Condensed Consolidated Balance Sheet.

Note 5. – Shareholders’ Equity

Tax Benefits Protection Rights Plan

On September 29, 2016, SunLink entered into a Tax Benefits Preservation Rights Plan (the “Tax Benefits Protection Rights Plan”). Effective September 29, 2016, the Board declared a dividend in the form of one preferred stock purchase right for each of the Company’s issued and outstanding common shares. The purpose of the Tax Benefits Protection Rights Plan is to diminish the risk that the Company’s ability to use its net operating losses and certain other tax assets to reduce potential future federal income tax obligations would become subject to limitations by reason of the Company experiencing an “ownership change,” as defined in Section 382 of the Code.

Stock-Based Compensation

For the three months ended September 30, 2016 and 2015, the Company recognized $49 and $30, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 72,000 and 30,000 share options granted under the 2011 Director Stock Option Plan during the three months ended September 30, 2016 and 2015, respectively. There were 45,000 share options granted under the 2005 Equity Incentive Plan during the three months ended September 30, 2015.

Note 6. – Revenue Recognition and Accounts Receivables

The Company’s subsidiaries recognize revenues in the period in which services are provided. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.

Revenues by payor were as follows for the three months ended September 30, 2016 and 2015:


	Three Months Ended
	September 30,
	2016			2015
Healthcare Facilities Segment:
Medicare	$	2,033		$	3,509
Medicaid		2,496			2,922
Self-pay		119			645
Managed Care & Other Insurance		720			2,402
Other		22			33

Revenues before provision for doubtful accounts		5,390			9,511
Provision for doubtful accounts		(33	)		(716	)

Healthcare Facilities Segment Net Revenues		5,357			8,795
Pharmacy Segment Net Revenues		7,341			7,567
Other Revenues		348			222

Total Net Revenues	$	13,046		$	16,584

The net revenues of the Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Summary information for accounts receivable is as follows:


	September 30,			June 30,
	2016			2016
Accounts receivable (net of contractual allowances)	$	6,698		$	7,157
Less allowance for doubtful accounts		(792	)		(991	)

Patient accounts receivable - net	$	5,906		$	6,166

The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Pharmacy Segment for the three months ended September 30, 2016 and 2015:


Three Months Ended September 30, 2016,	Healthcare Facilities			Pharmacy			Total
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		33			91			124
Discontinued Operations		407			—			407
Accounts written off, net of recoveries		(662	)		(68	)		(730	)

Balance at September 30, 2016	$	402		$	390		$	792


Three Months Ended September 30, 2015,	Healthcare Facilities			Pharmacy			Total
Balance at July 1, 2015	$	4,962		$	385		$	5,347
Additions recognized as a reduction to revenues:
Continuing Operations		715			222			1,004
Discontinued Operations		1,017			—			950
Accounts written off, net of recoveries		(1,913	)		(163	)		(2,076	)

Balance at September 30, 2015	$	4,781		$	444		$	5,225

Note 7. - Goodwill and Intangible Assets

SunLink’s goodwill and intangible assets are composed of:


	September 30,		June 30,
	2016		2016

Pharmacy Segment Goodwill	$	461	$	461

Intangibles consist of the following, net of amortization:


	September 30,			June 30,
	2016			2016

Pharmacy Segment Intangibles
Trade Name (non-amortizing)		2,000			2,000
Customer Relationships		1,089			1,089
Medicare License		769			769

		3,858			3,858
Accumulated Amortization		(1,198	)		(1,163	)


Total Intangibles	$	2,660		$	2,695

Amortization expense was $36 and $36 for the three months ended September 30, 2016 and 2015, respectively.

Note 8. –Long-Term Debt

Long-term debt consisted of the following:


	September 30,			June 30,
	2016			2016
Trace RDA Loan	$	7,575		$	7,698
SHPP RDA Loan		1,940			1,950
Carmichael Notes		0			1,508
Capital lease obligations and other		27			32

Total		9,542			11,188
Less unamortized debt issuance costs		(719	)		(736	)
Less current maturities		(7,113	)		(7,473	)

	$	1,710		$	2,979

Trace RDA Loan and Trace Working Capital Loan—On July 11, 2012, SunLink and two wholly owned subsidiaries of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) and a Working Capital Loan Agreement (“Trace Working Capital Loan”), both dated as of July 5, 2012.

The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at September 30, 2016). The Trace RDA Loan is collateralized by real estate and equipment of Trace Regional Hospital (“Trace”) in Houston, MS and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program.

The Trace Working Capital Loan as amended provided for a revolving line of credit which expired on July 2, 2016 and was not renewed. At June 30, 2016, there were no outstanding borrowings under the Trace Working Capital Loan.

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. At September 30, 2016 and June 30, 2016, Trace was not in compliance with the debt service coverage, fixed charge ratio and funded debt to EBITDA ratios. No modification or waiver for the September 30, 2016 nor the June 30, 2016 non-compliance has been obtained as of November 10, 2016 and accordingly, the indebtedness of $7,575 as of September 30, 2106 and $7,698 as of June 30, 2016 are presented in current liabilities in the condensed consolidated balance sheets for these dates. The Company is discussing a modification or waiver of this non-compliance with the lender. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash flows, including from operating activities. If Trace is unable to generate sufficient cash flow from operations to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary.

SHPP RDA Loan—On November 6, 2012, SunLink Healthcare Professional Property, LLC (“SHPP”), a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”). SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia.

the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and one subsidiary. SHPP has entered into an agreement to sell the medical office which is the collateral under this loan, and the loan will be paid off upon the sale, if it is consummated.

Carmichael Notes—On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Notes”). The Carmichael Notes, as amended, were payable in semi-annual installments of $185 of principal and plus accrued interest, with the remaining balance of $1,255 due October 22, 2017. Under an agreement dated September 9, 2016, between the Company and the Note holders, the Carmichael Notes balance of $1,508 was paid in full on September 9, 2016 and the accrued interest payable to that date of $46 was forgiven. A gain on retirement of debt of $46 for the three months ended September 30, 2016 was reported for the interest payable forgiveness.

ASU 2015-3, “Simplifying the Presentation of Debt Issuance Costs” — In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-3, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-3”). ASU 2015-3 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts, rather than separately as an asset. The Company adopted the provisions of ASU 2015-3 on July 1, 2016 and retrospectively for all periods presented. The adoption of ASU 2015-3 had no impact on the Company’s results of operations or cash flows.

The following is a summary of the line items impacted by the adoption of ASU 2015-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet:


	As Originally Reported		Adjustments for the Adoption of ASU 2015-3			As Currently Reported
Prepaid expense and other current assets	$	2,777	$	(9	)	$	2,768
Total current assets	$	17,901	$	(9	)	$	17,892
Other noncurrent assets	$	1,459	$	(727	)	$	732
Total noncurrent assets	$	13,946	$	(727	)	$	13,219
Total Assets	$	44,841	$	(736	)	$	44,105
Current maturities of long-term debt	$	8,012	$	(539	)	$	7,473
Total current liabilities	$	20,590	$	(539	)	$	20,051
Long-term debt	$	3,176	$	(197	)	$	2,979
Total long-term liabilities	$	4,762	$	(197	)	$	4,565
Total Liabilities and Shareholders’ Equity	$	44,841	$	(736	)	$	44,105

Note 9. – Income Taxes

Income tax expense of $144 ($210 federal tax expense and $66 state tax benefit) and income tax benefit of $249 ($229 federal tax benefit and $20 state tax benefit) was recorded for continuing operations for the three months ended September 30, 2016 and 2015, respectively.

In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates.

At September 30, 2016, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $10,818 against the deferred tax asset so that there is a net deferred income tax liability of $378 at September 30, 2016. A $378 net deferred long-term income tax liability is recorded at September 30, 2016 as required under interim reporting guidance of ASC 740-270. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans.

The principal negative evidence that led us to determine at September 30, 2016 that all the deferred tax assets should have a full valuation allowances of the net deferred income tax assets was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Facilities Segment businesses operate. The deferred income tax liability of $378 at September 30, 2016 will be adjusted quarterly as required under the requirements for interim reporting guidance of ASC 740-270.

For Federal income tax purposes, at September 30, 2016, the Company had approximately $10,000 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382.

Note 10. – Commitments and Contingencies

Sale of Hospital Facilities — The Company has sold four hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and liabilities. – See Note 3 Discontinued Operations.

Contractual Obligations, Commitments and Contingencies

Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at September 30, 2016 were as follows:


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	7,637	$	461	$	519
2 years		51		368		104
3 years		47		303		101
4 years		49		255		98
5+ years		1,758		74		746

	$	9,542	$	1,461	$	1,568

Note 11. - Related Party Transactions

A director of the Company and the Company’s former corporate secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $197 and $84 for legal services to these law firms in the three months ended September 30, 2016 and 2015, respectively. Included in the Company’s condensed consolidated balance sheets at September 30, 2016 and June 30, 2016 is $168 and $75, respectively, of amounts payable to these law firms.

Note 12. - Financial Information by Segment

Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Facilities and Pharmacy.

We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of September 30, 2016 and 2015 and for the three months then ended is as follows:


	Healthcare						Corporate
	Facilities			Pharmacy			and Other			Total
As of and for the three months ended September 30, 2016
Net revenues from external customers	$	5,455		$	7,341		$	250		$	13,046
Operating profit (loss)		78			(192	)		(839	)		(953	)
Depreciation and amortization		173			254			17			444
Assets		13,686			11,420			15,557			40,663
Expenditures for property, plant and equipment		54			189			1			244

As of and for the three months ended September 30, 2015
Net revenues from external customers	$	8,795		$	7,567		$	222		$	16,584
Operating profit (loss)		(498	)		(79	)		(589	)		(1,166	)
Depreciation and amortization		181			198			48			427
Assets		27,080			11,855			16,360			55,295
Expenditures for property, plant and equipment		35			428			0			463

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share and admissions data)

Forward-Looking Statements

This Quarterly Report and the documents that are incorporated by reference in this Quarterly Report contain certain forward-looking statements within the meaning of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to:

General Business Conditions

•

general economic and business conditions in the U.S., both nationwide and in the states in which we operate;

•

increases in uninsured and/or underinsured patients due to unemployment or other conditions, higher deductibles and co-insurance, or other terms of health insurance coverage resulting in higher bad debt amounts;

•

the competitive nature of the U.S. community hospital, nursing home and pharmacy businesses;

•

demographic changes in areas where we operate;

•

the availability of cash or borrowings to fund working capital, renovations, replacements, expansions and capital improvements at existing healthcare and pharmacy facilities and for acquisitions and replacement of such facilities;

•

changes in accounting principles generally accepted in the U.S.; and,

•

fluctuations in the market value of equity securities including SunLink common shares.

Operational Factors

•

ability or inability to operate profitably in one or more segments of the healthcare business;

•

the availability of, and our ability to attract and retain, sufficient qualified staff physicians, management, nurses, pharmacists and staff personnel for our operations;

•

timeliness and amount of reimbursement payments received under government programs;

•

the ability or inability to obtain external financing for working capital included under lending agreements;

•

changes in interest rates under lending agreements and other indebtedness;

•

the ability or inability to refinance former or existing indebtedness and defaults or potential defaults under existing indebtedness;

•

restrictions imposed by existing or future lending and other indebtedness;

•

the cost and availability of insurance coverage including professional liability (e.g., medical malpractice) and general liability insurance;

•

the efforts of insurers, healthcare providers, government payors and others to contain healthcare costs;

•

the impact on hospital services of the treatment of patients in lower acuity healthcare settings, whether with drug therapy or in alternative healthcare settings, such as surgery centers or urgent care centers;

•

changes in medical and other technology;

•

risks of changes in estimates of self insurance claims and reserves;

•

changes in prices of materials and services utilized in our Healthcare Facilities and Pharmacy Segments;

•

changes in wages as a result of inflation or competition for management, physician, nursing, pharmacy and staff positions;

•

changes in the amount and risk of collectability of accounts receivable, including deductibles and co-pay amounts;

•

the functionality or costs with respect to our information systems for our Healthcare Facilities and Pharmacy Segments and our corporate office, including both software and hardware; and

•

the availability of and competition from alternative drugs or treatments provided by our Pharmacy Segment; and

•

the restrictions, processes and conditions relating to our Pharmacy Segment imposed by pharmacy benefit providers, drug manufacturers and distributors.

Liabilities, Claims, Obligations and Other Matters

•

claims under leases, guarantees, disposition agreements, and other obligations relating to discontinued operations, including claims from sold or leased facilities, retained liabilities, or retained subsidiaries;

•

potential adverse consequences of known and unknown government investigations;

•

claims for product and environmental liabilities from continuing and discontinued operations;

•

professional, general and other claims which may be asserted against us; and,

•

natural disasters and weather-related events such as earthquakes, hurricanes, flooding, snow, ice and wind damage and population evacuations affecting areas in which we operate.

Regulation and Governmental Activity

•

existing and proposed governmental budgetary constraints;

•

Federal and state insurance exchanges and their rules on reimbursement terms;

•

the decision by states in which we operate hospitals (Georgia and Mississippi) to not expand Medicaid;

•

the regulatory environment for our businesses, including state certificate of need laws and regulations, pharmacy licensing laws and regulations, rules and judicial cases relating thereto;

•

adverse changes in the levels and terms of government (including Medicare, Medicaid and other programs) and private reimbursement for SunLink’s healthcare services including the payment arrangements and terms of managed care agreements; EHR reimbursement and indigent care reimbursements (Medicare Upper Payment Limit “UPL” and Disproportionate Share Hospital “DSH” adjustments);

•

changes in or failure to comply with Federal, state or local laws and regulations affecting our Healthcare Facilities and Pharmacy Segments; and,

•

the possible enactment of additional Federal healthcare reform laws or reform laws in states where our subsidiaries operate hospital and pharmacy facilities (including Medicaid waivers, bundled payments, accountable care and similar organizations, competitive bidding, and other reforms).

Dispositions, Acquisitions, and Renovation Related Matters

•

the ability to dispose of underperforming facilities;

•

the availability and terms of capital to fund acquisitions, improvements, renovations or replacement facilities; and

•

competition in the market for acquisitions of hospitals, pharmacy facilities and other healthcare businesses.

The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect SunLink in an adverse manner.

You should read this Quarterly Report completely and with the understanding that actual future results may be materially different from what we expect. You are cautioned not to unduly rely on forward-looking statements when evaluating the information presented in this Quarterly Report or our other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of SunLink.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. We disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based, except as required by applicable law. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and the other risk factors set forth elsewhere in this report and in our Annual Report on Form 10-K.

Business Strategy: Operations, Dispositions and Acquisitions

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

•

it requires assumptions to be made that were uncertain at the time the estimate was made; and

•

changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates are more fully described in our 2016 Annual Report on Form 10-K and continue to include the following areas:

•

Receivables – net and provision for doubtful accounts;

•

Revenue recognition / Net Patient Service Revenues;

•

Goodwill, intangible assets and accounting for business combinations;

•

Professional and general liability claims; and

•

Accounting for income taxes

Financial Summary

The results of continuing operations shown in the financial summary below are for our two business segments, Healthcare Facilities and Pharmacy.


	Three Months Ended
	September 30,
	2016			2015			% Change
Net Revenues - Healthcare Facilities	$	5,455		$	8,795			-38.0	%
Net Revenues - Pharmacy		7,341			7,567			-3.0	%
Other Revenues		250			222			12.6	%

Total Net Revenues		13,046			16,584			-21.3	%
Costs and expenses		(13,999	)		(17,750	)		-21.1	%

Operating profit (loss)		(953	)		(1,166	)		18.3	%
Interest expense - net		(221	)		(217	)		1.8	%
Ganin on extinguishment of debt		46			0			NA
Gain on sale of assets		22			1			2100.0	%

Earning (Loss) from continuing operations before income taxes	$	(1,106	)	$	(1,382	)		20.0	%


Healthcare Facilities Segment:
Hospital and Nursing Home Admissions		124			269			-54	%
Nursing Home Patient Days		14,433			14,521			-1	%

Results of Operations

Healthcare Facilities Segment Net Revenues

The following table sets forth the percentage of net patient revenues from major payors for the Healthcare Facilities Segment for the periods indicated:


	Three Months Ended
	September 30,
	2016			2015
Source:
Medicare		37.9	%		37.1	%
Medicaid		46.5	%		30.8	%
Managed Care Insurance & Other		13.4	%		25.3	%
Self-pay		2.2	%		6.8	%

		100.0	%		100.0	%

The Healthcare Facilities Segment in the current year is composed of two nursing homes, one hospital and two leased medical office buildings. During the three months ended September 30, 2015, the segment operated a second hospital on the same site as one of the nursing home, but closed this hospital in June 2016. Healthcare Facilities net revenues decreased $3,340 for the three months ended September 30, 2016, compared to the prior year period primarily as a result of closing a hospital. Excluding the closed hospital from the prior year net revenues, the net revenues increased $255 in the current year. Net revenues from all payer sources decreased compared to last year.

Pharmacy Segment Net Revenues

Pharmacy Segment net revenues for the three months ended September 30, 2016 decreased $226, or 3%, from the three months ended September 30, 2015. The decrease was a result of a 14% decrease in Durable Medical Equipment (“DME”) partially offset by a 3% increase in Institutional Pharmacy net revenues and a 1% increase in Retail Pharmacy net revenues. DME net revenues decreased primarily due to the negative effect of the expansion in January 2016 of Medicare Competitive Bidding in its service area. The average net revenue per DME sales order decreased 15% in the current year, primarily due to the Competitive Bidding expansion.

Healthcare Facilities Segment Cost and Expenses

Costs and expenses for our Healthcare Facilities Segment, including depreciation and amortization, were $5,377 and $9,293 for the three months ended September 30, 2016 and 2015, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended
	September 30,
	2016			2015
Salaries, wages and benefits		64.3	%		67.4	%
Supplies		7.4	%		10.1	%
Purchased services		8.4	%		8.0	%
Other operating expenses		14.7	%		17.0	%
Rent and lease expense		0.6	%		1.1	%
Depreciation and amortization expense		3.2	%		2.1	%

All expense categories except purchased services and depreciation and amortization decreased as a percentage of net revenues for the three months ended September 30, 2016. Purchased services expense decreased $244, or 35%, in the current year but the lower net revenues resulted in the percentage increase. Similarly, depreciation and amortization expense decreased $8 this year. The $3,916 decrease in costs and expenses is due to the closure of one hospital included in the three months ended September 30, 2015.

Pharmacy Segment Cost and Expenses

Cost and expenses for our Pharmacy Segment, including depreciation and amortization, were $7,533 and $7,646 for the three months ended September 30, 2016 and 2015, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended
	September 30,
	2016			2015
Cost of goods sold		63.2	%		60.8	%
Salaries, wages and benefits		25.4	%		24.7	%
Provision for bad debts		1.2	%		2.9	%
Supplies		0.5	%		0.3	%
Purchased services		4.0	%		4.0	%
Other operating expenses		3.8	%		4.5	%
Rent and lease expense		1.1	%		1.2	%
Depreciation and amortization expense		3.5	%		2.6	%

Cost of goods sold as a percent of net revenues increased in the three months ended September 30, 2016 as compared to the comparable periods of the prior year due to cost of certain generic drugs and sales product mix for the current period.

Salaries, wages and benefits as a percent of net revenues increased in the three month period ended September 30, 2016 due to lower net revenues although actual expense decreased $5 in the current year. Provision for bad debts decreased during the current year due to improved credit and collections practices. Depreciation and amortization expense increased $56 this year due to increased depreciation for capitalized rental DME.

Operating Profit and Loss

The Company reported an operating loss of $953 for the three months ended September 30, 2016 compared to an operating loss of $1,166 for the three months ended September 30, 2015. The lower operating loss for the three months ended September 30, 2016 compared to the operating loss for the prior year’s three month period resulted from the closure of one hospital in June 2016.

Interest Expense

Interest expense was $221 and $217 for the three months ended September 30, 2016 and 2015, respectively. A gain on extinguish of debt of $46 for the three months ended September 30, 2016 resulted from accrued interest forgiveness by the debt holder as a condition of early repayment of $1,508 of debt.

Income Taxes

At September 30, 2016, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $10,818 against the deferred tax asset so that there is a net deferred income tax liability of $378 at September 30, 2016. A $378 net deferred long-term income tax liability is recorded at September 30, 2016 as required under the intraperiod income tax allocation requirements of ASC 740. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans.

Loss from Continuing Operations before Income Tax

Loss from continuing operations before income tax of $1,106 for the three months ended September 30, 2016 compared to a loss from continuing operations before income tax of $1,382 for the three months ended September 30, 2015. Despite the $3,538 decrease in net revenues in the three months ended September 30, 2016 when compared to the same quarter last year, the $576 reduction in Healthcare Facilities Segment’s operating loss, offset by an increase of $113 in operating loss by the Pharmacy Segment and $250 in operating loss by Corporate and Other, resulted in the $213 reduced loss from continuing operations this year compared to last year. The $250 increase in Corporate and Other operating loss resulted from increased legal expenses needed for the defense of a lawsuit.

Earnings (Loss) After Taxes

Loss from continuing operations was $1,250 (a loss of $0.13 per fully diluted share) for the three months ended September 30, 2016 compared to a loss from continuing operations of $1,133 ($0.12 per fully diluted share) for the three months ended September 30, 2015. The increased loss in the current year resulted from $144 income tax expense in the three months ended September 30, 2016 which compares to the $535 income tax benefit recorded in the three months ended September 30, 2015 as a result of the $4,273 deferred income tax valuation analysis this year.

Earnings from discontinued operations of $4,273 (including a gain on sale of Chestatee of $7,246 and income tax expense of $2,634) for the three months ended September 30, 2016, which compares to a loss from discontinued operations of $535 for the three months ended September 30, 2015. The

Net income for the three months ended September 30, 2016 was $3,023 (or $0.32 fully diluted share) compared to net loss of $1,668 (a loss of $0.18 earnings per fully diluted share) for the three months ended September 30, 2015.

Adjusted earnings before income taxes, interest, depreciation and amortization

Earnings before income taxes, interest, depreciation and amortization (“EBITDA”) represent the sum of income before income taxes, interest, depreciation and amortization. We understand that certain industry analysts and investors generally consider EBITDA to be one measure of the liquidity of a company, and it is presented to

assist analysts and investors in analyzing the ability of a company to generate cash, service debt and meet capital requirements. We believe increased EBITDA is an indicator of improved ability to service debt and to satisfy capital requirements. EBITDA, however, is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income as a measure of operating performance or to cash liquidity. Because EBITDA is not a measure determined in accordance with accounting principles generally accepted in the United States of America and is thus susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other corporations. Where we adjust EBITDA for non-cash charges, we refer to such measurement as “Adjusted EBITDA”, which we report on a Company wide basis. Non-cash adjustments in Adjusted EBITDA are not intended to be identified or characterized in any respect as “non-recurring, infrequent or unusual,” if we believe such charge is reasonably likely to recur within two years, or if there was a similar charge (or gain) within the prior two years. Where we report Adjusted EBITDA, we typically also report Healthcare Facilities Segment Adjusted EBITDA and Pharmacy Segment Adjusted EBITDA which is the EBITDA for the applicable segments without any allocation of corporate overhead, which we report as a separate line item, without gains on sales of businesses and without any allocation of the non-cash adjustments, which we also report as a separate line item in Adjusted EBITDA. Net cash used in operations for the three months ended September 30, 2016 and 2015, respectively, is shown below.


	Three Months Ended
	September 30,
	2016			2015
Healthcare Facilities Adjusted EBITDA	$	251		$	(317	)
Pharmacy Adjusted EBITDA		62			119
Corporate overhead costs		(822	)		(541	)
Taxes and interest expense		(365	)		32
Other non-cash expenses and net change in operating assets and liabilities		(2,316	)		(108	)

Net cash used in operations	$	(3,190	)	$	(815	)

Liquidity and Capital Resources

Overview

Our primary source of liquidity is the cash on hand of $12,801 at September 30, 2016. Currently, the Company’s ability to raise capital (debt or equity) in the public or private markets on what it considers acceptable terms is uncertain. We nevertheless periodically seek options to obtain financing for the liquidity needs of the Company or individual subsidiaries. The Company and its subsidiaries currently are funding working capital needs primarily from cash on hand and from the sale of assets. See “Subsidiary Loans” below.

The Company believes its Healthcare Facilities Segment and its Pharmacy Segment business continue to underperform. The Company has incurred losses from continuing operations in eight of the last nine fiscal quarters through the quarter ending September 30, 2016. See the “Business Strategy: Operations, Dispositions and Acquisitions” discussion earlier in this Item 2.

Subject to the risks and uncertainties discussed herein, we believe we have adequate financing and liquidity to support our current level of operations through the next twelve months.

Subsidiary Loans

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. At September 30, 2016 and June 30, 2016, Trace was not in compliance with the debt service coverage, fixed charge ratio and funded debt to EBITDA ratios. No modification or waiver for the September 30, 2016 nor the June 30, 2016 non-compliance has been obtained as of November 10, 2016 and the indebtedness of $7,575 as of September 30, 2016 and $7,698 as of June 30, 2016 are presented in current liabilities in the condensed consolidated balance sheets for these dates. The Company is discussing a modification or waiver of this non-compliance with the lender. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash flows, including from operating activities. If Trace is unable to generate sufficient cash flow from operations to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary.

SHPP RDA Loan—On November 6, 2012, SunLink Healthcare Professional Property, LLC “SHPP”, a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”). SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia.

The SHPP RDA Loan has a term of 25 years with monthly payments of principal and interest until repaid. The SHPP RDA Loan bears interest at a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5% (5.50% at September 30, 2016). The SHPP RDA Loan is collateralized by SHPP’s real estate, equipment and leases and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. The SHPP RDA Loan contains certain financial covenants with respect to the ratio of current assets to current liabilities and debt service coverage, all as defined in the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and one subsidiary. SHPP has entered into an agreement to sell the medical office which is the collateral under this loan, and the loan will be paid off upon the sale, if it is consummated.

Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	7,637	$	461	$	419
2 years		51		368		103
3 years		47		303		101
4 years		49		255		98
5+ years		1,758		74		847

	$	9,542	$	1,461	$	1,568

At September 30, 2016, we had outstanding long-term debt of $9,542 of which $7,575 was incurred under the Trace RDA Loan, $1,940 was incurred under the SHPP RDA Loan and $27 was related to other debt.

Discontinued Operations

Chestatee Hospital—On August 19, 2016, the Company’s subsidiary Southern Health Corporation of Dahlonega, Inc. (“Chestatee”) sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,246 is subject to adjustment for various purchase price adjustments. Chestatee retained certain liabilities, including for employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds have been used for the payment of debt and the balance will be retained for working capital and general corporate purposes. The assets sold and liabilities assumed are shown as assets held for sale in the condensed consolidated balance sheet as of June 30, 2016.

Related Party Transactions

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have not entered into any transactions using derivative financial instruments or derivative commodity instruments and believe that our exposure to market risk associated with other financial instruments (such as investments and borrowings) and interest rate risk is not material.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 and Rule 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this report, we carried out an evaluation of the effectiveness of the design and operation of our Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and the changes in our disclosure controls and procedures during the quarter. Under the direction of our principal executive officer and principal financial officer, we evaluated our disclosure controls and procedures and internal control over financial reporting and concluded that our disclosure controls and procedures were effective as of September 30, 2016.

Disclosure controls and procedures and other procedures are designed to ensure that information required to be disclosed in our reports or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based on an evaluation of the effectiveness of disclosure controls and procedures performed in connection with the preparation of this Form 10-Q, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2016.

Changes in Internal Control Over Financial Reporting

There were no changes during the quarter ended September 30, 2016 in our internal control over financial reporting that materially affected, or is likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Items required under Part II not specifically shown below are not applicable.

ITEM 1A.

RISK FACTORS

Risk Factors Relating to an Investment in SunLink

Information regarding risk factors appears in “MD&A – Forward-Looking Statements,” in Part I – Item 2 of this Form 10-Q and in “MD&A -Risks Factors Relating to an Investment in SunLink” in Part I – Item 1A of the Company’s Annual Report on Form 10-K for the year ended June 30, 2016. While we believe there have been no material changes from the risk factors previously disclosed in such Annual Report except as set forth herein, you should carefully consider, in addition to the other information set forth in this report, the risk factors discussed in our Annual Report which could materially affect our business, financial condition or future results. Such risk factors are expressly incorporated herein by reference. The risks described in our Annual Report are not the only risks facing our Company. In addition to risks and uncertainties inherent in forward-looking statements contained in this Report on Form 10-Q, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Whenever we refer to “SunLink,” “Company”, “we,” “our,” or “us” in this Item 1A, we mean SunLink Health Systems, Inc. and its subsidiaries, unless the context suggests otherwise.

ITEM 6.

EXHIBITS

Exhibits:


31.1		Chief Executive Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2		Chief Financial Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1		Chief Executive Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Chief Financial Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Company’s quarterly report on Form 10-Q for the three months ended September 30, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of September 30, 2016 (unaudited) and June 30, 2016, (ii) Condensed Consolidated Statements of Operations for the three months ended September 30, 2016 and 2015 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2016 and 2015 (unaudited), and (iv) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, SunLink Health Systems, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


SunLink Health Systems, Inc.

By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

Dated: November 10, 2016

EX-31.1 2 d215332dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Robert M. Thornton, Jr., the Chief Executive Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended September 30, 2016 (the “report”);

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of September 30, 2016 (the “Evaluation Date”), based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


November 10, 2016		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		SunLink Health Systems, Inc.
		Chief Executive Officer

EX-31.2 3 d215332dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Mark J. Stockslager, the Chief Financial Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended September 30, 2016 (the “report”);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


November 10, 2016		/s/ Mark J. Stockslager
		Mark J. Stockslager
		SunLink Health Systems, Inc.
		Chief Financial Officer

EX-32.1 4 d215332dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2016, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Robert M. Thornton, Jr., Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		Chief Executive Officer

November 10, 2016

EX-32.2 5 d215332dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2016, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Mark J. Stockslager, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

November 10, 2016

EX-101.INS 6 ssy-20160930.xml XBRL INSTANCE DOCUMENT

2100000

1255000

4900000

9443408

0.08

3000000

55295000

5225000

4506000

16360000

11855000

27080000

444000

4781000

2347000

81000

20686000

9444000

40663000

24038000

10818000

13588000

792000

27000

12801000

4722000

2160000

378000

2136000

-420000

378000

6698000

1042000

10000000

2000000

1710000

9542000

7113000

3738000

2660000

2323000

1621000

40663000

461000

519000

14364000

5933000

676000

10692000

31378000

22561000

4671000

2000000

3008000

719000

5906000

1131000

15557000

11420000

13686000

0.060

7575000

0.06

0.0550

1940000

0.05

51000

7637000

9542000

1758000

47000

49000

104000

519000

1568000

746000

101000

98000

368000

461000

1461000

74000

303000

255000

2000000

1089000

769000

390000

1198000

2660000

461000

3858000

402000

168000

9975000

5347000

5974000

385000

4962000

2872000

2000

20920000

9444000

44105000

17892000

13539000

991000

32000

3261000

1698000

4722000

3391000

624000

7633000

-420000

2461000

7157000

1883000

2000000

2979000

11188000

7473000

4565000

2695000

2612000

1685000

44105000

461000

425000

20051000

13219000

2745000

732000

12994000

33914000

19489000

1648000

2000000

2768000

736000

6166000

1161000

1508000

7698000

1950000

2000000

1089000

769000

367000

1163000

2695000

461000

3858000

624000

75000

44841000

17901000

3176000

8012000

4762000

44841000

20590000

13946000

1459000

2777000

-736000

-9000

-197000

-539000

-197000

-736000

-539000

-727000

-9000

7246000

15000000

1508000

46000 3

-229000

283000

-1468000

30000

-0.18

427000

-0.18

-1668000

36000

4597000

-818000

-20000

869000

-535000

2076000

16584000

200000

201000

8317000

-1668000

2201000

222000

217000

-0.06

716000

-815000

-175000

-0.06

1000

-1166000

-478000

76000

-1133000

-0.12

-1382000

-249000

463000

-0.12

9443000

916000

9443000

175000

17300000 463000 15000 0

48000

222000

-589000

198000

7567000

-79000

428000

181000

8795000

-498000

35000

-818000

3988000

-36000

-594000

3888000

-188000

100000

30000

45000

645000 2402000 2922000 33000 3509000

28000

16000

8000

36000

1004000

222000

715000

950000

1017000

163000

7567000

1913000

8795000

716000

9511000 222000

84000

SUNLINK HEALTH SYSTEMS INC

<div> Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at September 30, 2016 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,637</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">519</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">368</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">303</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">101</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">255</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,758</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">746</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,542</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,568</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

210000

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Note 3. – Discontinued Operations <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Results for all of the businesses included in discontinued operations are presented in the following table: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" nowrap="nowrap" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,101</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,888</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(234</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,867</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,988</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Earnings (loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(64</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(594</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(238</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(188</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Earnings (loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(339</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(818</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Gain on Sale: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,246</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,246</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(818</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense (benefit) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,634</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">283</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,273</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(535</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Chestatee Hospital—On August 19, 2016, the Company’s subsidiary Southern Health Corporation of Dahlonega, Inc. (“Chestatee”) sold substantially all of the assets and certain liabilities of Chestatee Regional Hospital in Dahlonega, Georgia through an asset purchase agreement for $15,000 subject to adjustment for the book value of certain assets and certain liabilities assumed at the sale date. The pre-tax gain on sale of $7,246 is subject to adjustment for various purchase price adjustments. Chestatee retained certain liabilities, including for employee related liabilities and certain Medicare and Medicaid liabilities, relating to the period it owned and operated the hospital. A portion of the net proceeds have been used for the payment of debt. The assets sold and liabilities assumed are shown as assets held for sale in our consolidated balances as of June 30, 2016. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Other Sold Hospitals – Subsidiaries of the Company have sold substantially all of the assets of three hospitals (“Other Sold Hospitals”) during the period July 2, 2012 to December 31, 2014. Certain assets and liabilities were retained in these sales and the results of the retained assets and liabilities are classified as discontinued operations in our condensed consolidated financial statements for the three month periods ended September 30, 2016 and 2015. The loss before income taxes of the Other Sold Hospitals results primarily from negative prior year Medicare and Medicare cost report settlements. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three months ended September 30, 2016 and 2015. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The components of pension expense for the three months ended September 30, 2016 and 2015, respectively, were as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" nowrap="nowrap" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> SunLink contributed $35 to the plan in the three months ended September 30, 2016 and expects to contribute an additional $105 during the last three quarter of the fiscal year ending June 30, 2017. </div>

10-Q 0000096793

<div> Note 7. - Goodwill and Intangible Assets SunLink’s goodwill and intangible assets are composed of:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Goodwill </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,198</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,163</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,660</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,695</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Amortization expense was $36 and $36 for the three months ended September 30, 2016 and 2015, respectively. </div>

2634000

2016-09-30

9540000

49000

2017 false --06-30

0.32

444000

0.32

3023000

Smaller Reporting Company

36000

4636000

-339000

-66000

708000

<div> Note 10. – Commitments and Contingencies Sale of Hospital Facilities — The Company has sold four hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and liabilities. – See Note 3 Discontinued Operations.   Contractual Obligations, Commitments and Contingencies Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at September 30, 2016 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,637</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">519</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">368</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">47</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">303</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">101</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">255</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,758</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">746</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,542</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,568</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

4273000

730000

13046000

206000

129000

<div> Note 9. – Income Taxes Income tax expense of $144 ($210 federal tax expense and $66 state tax benefit) and income tax benefit of $249 ($229 federal tax benefit and $20 state tax benefit) was recorded for continuing operations for the three months ended September 30, 2016 and 2015, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. At September 30, 2016, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $10,818 against the deferred tax asset so that there is a net deferred income tax liability of $378 at September 30, 2016. A $378 net deferred long-term income tax liability is recorded at September 30, 2016 as required under interim reporting guidance of ASC 740-270. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at September 30, 2016 that all the deferred tax assets should have a full valuation allowances of the net deferred income tax assets was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Facilities Segment businesses operate. The deferred income tax liability of $378 at September 30, 2016 will be adjusted quarterly as required under the requirements for interim reporting guidance of ASC 740-270. For Federal income tax purposes, at September 30, 2016, the Company had approximately $10,000 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. </div>

5845000

3023000

1710000

91000

221000

0.45

33000

-3190000

46000

-1646000

0.45

14620000

22000

-953000

14376000

<div> Note 8. –Long-Term Debt Long-term debt consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,575</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,698</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> SHPP RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,940</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,950</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Carmichael Notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,508</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Capital lease obligations and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,542</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,188</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(719</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,113</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,473</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,710</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Trace RDA Loan and Trace Working Capital Loan—On July 11, 2012, SunLink and two wholly owned subsidiaries of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) and a Working Capital Loan Agreement (“Trace Working Capital Loan”), both dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at September 30, 2016). The Trace RDA Loan is collateralized by real estate and equipment of Trace Regional Hospital (“Trace”) in Houston, MS and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. The Trace Working Capital Loan as amended provided for a revolving line of credit which expired on July 2, 2016 and was not renewed. At June 30, 2016, there were no outstanding borrowings under the Trace Working Capital Loan. The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. At September 30, 2016 and June 30, 2016, Trace was not in compliance with the debt service coverage, fixed charge ratio and funded debt to EBITDA ratios. No modification or waiver for the September 30, 2016 nor the June 30, 2016 non-compliance has been obtained as of November 10, 2016 and accordingly, the indebtedness of $7,575 as of September 30, 2106 and $7,698 as of June 30, 2016 are presented in current liabilities in the condensed consolidated balance sheets for these dates. The Company is discussing a modification or waiver of this non-compliance with the lender. The ability of Trace to continue to make the required debt service payments under the Trace RDA Loan depends on, among other things, its ability to generate sufficient cash flows, including from operating activities. If Trace is unable to generate sufficient cash flow from operations to meet debt service payments on the Trace RDA Loan, including in the event the lender were to declare an event of default and accelerate the maturity of the indebtedness, such failure could have material adverse effects on the Company. The Trace RDA Loan is guaranteed by the Company and one subsidiary. SHPP RDA Loan—On November 6, 2012, SunLink Healthcare Professional Property, LLC (“SHPP”), a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”). SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia. The SHPP RDA Loan has a term of 25 years with monthly payments of principal and interest until repaid. The SHPP RDA Loan bears interest at a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5% (5.50% at September 30, 2016). The SHPP RDA Loan is collateralized by SHPP’s real estate, equipment and leases and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. The SHPP RDA Loan contains certain financial covenants with respect to the ratio of current assets to current liabilities and debt service coverage, all as defined in the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and one subsidiary. SHPP has entered into an agreement to sell the medical office which is the collateral under this loan, and the loan will be paid off upon the sale, if it is consummated. Carmichael Notes—On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Notes”). The Carmichael Notes, as amended, were payable in semi-annual installments of $185 of principal and plus accrued interest, with the remaining balance of $1,255 due October 22, 2017. Under an agreement dated September 9, 2016, between the Company and the Note holders, the Carmichael Notes balance of $1,508 was paid in full on September 9, 2016 and the accrued interest payable to that date of $46 was forgiven. A gain on retirement of debt of $46 for the three months ended September 30, 2016 was reported for the interest payable forgiveness. ASU 2015-3, “Simplifying the Presentation of Debt Issuance Costs” — In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-3, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-3”). ASU 2015-3 requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts, rather than separately as an asset. The Company adopted the provisions of ASU 2015-3 on July 1, 2016 and retrospectively for all periods presented. The adoption of ASU 2015-3 had no impact on the Company’s results of operations or cash flows. The following is a summary of the line items impacted by the adoption of ASU 2015-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">As Originally Reported</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Adjustments for the Adoption of ASU 2015-3</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">As Currently Reported</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expense and other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,777</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,768</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,901</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,892</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other noncurrent assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,459</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(727</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total noncurrent assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,946</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(727</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,219</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total Assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,841</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,105</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Current maturities of long-term debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,012</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,473</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total current liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,590</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,051</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Long-term debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,176</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total long-term liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,762</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,565</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total Liabilities and Shareholders’ Equity </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,841</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,105</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

33000

-1250000

-0.13

<div> Note 1. –Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of September 30, 2016 and for the three month periods ended September 30, 2016 and 2015 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2016 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2016, filed with the SEC on September 30, 2016. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three month period ended September 30, 2016 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. </div>

-1106000

144000

<div> Note 2. – Business Operations Business Operations SunLink owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The Healthcare Facilities Segments, which is composed of:</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">A subsidiary which owns and operates an 84-licensed-bed, acute care hospital, which includes an 18-bed GPU, and a 66-bed nursing home.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">A subsidiary which owns and operates a 100-bed nursing home. This subsidiary also owns a hospital building and leases the portion of that building occupied by the emergency department to an unaffiliated healthcare provider.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Two separate subsidiaries which own medical buildings, which are leased to unaffiliated healthcare providers.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">A subsidiary which owns a closed hospital building and a medical office building which it currently rents office space to one unaffiliated healthcare provider.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The Specialty Pharmacy Segment, which is composed of four operational areas:</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Retail pharmacy products and services, all of which are conducted in rural markets;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Institutional pharmacy services;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Specialty pharmacy services; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Durable medical equipment.</td> </tr> </table> Our Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary.   The business strategy of SunLink is to focus its efforts on improving internal operations of the existing pharmacy business and healthcare facilities subsidiaries and on the sale or disposition of its subsidiaries’ underperforming assets. The Company considers the disposition of facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments and competition from existing and potential competitors, capital improvement needs, prevailing reimbursement rates for drugs and medical services under various Federal and state programs (e.g., Medicare and Medicaid) and by private payors, corporate strategy and other corporate objectives. The Company also is considering potential upgrades and improvements to certain of its healthcare facilities. The Company believes its Healthcare Facilities Segment and its Pharmacy Segment continues to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its specialty pharmacy business. The Company also has an agreement, subject to various conditions, to sell a medical office building. The Company has used cash proceeds from recent dispositions of assets to pay off certain liabilities and may use a portion of its existing cash assets, as well as any net proceeds from future dispositions, to prepay long-term debt, return capital to shareholders via a repurchase of shares or a dividend, make improvements to existing facilities, and for other general corporate purposes. There can be no assurance that any further dispositions will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that the publicly traded Company or any particular subsidiary of the Company owns or operates any asset, business or property. The Trace Hospital, pharmacy operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc. </div>

244000

-0.13

<div> Note 5. – Shareholders’ Equity Tax Benefits Protection Rights Plan On September 29, 2016, SunLink entered into a Tax Benefits Preservation Rights Plan (the “Tax Benefits Protection Rights Plan”). Effective September 29, 2016, the Board declared a dividend in the form of one preferred stock purchase right for each of the Company’s issued and outstanding common shares. The purpose of the Tax Benefits Protection Rights Plan is to diminish the risk that the Company’s ability to use its net operating losses and certain other tax assets to reduce potential future federal income tax obligations would become subject to limitations by reason of the Company experiencing an “ownership change,” as defined in Section 382 of the Code. Stock-Based Compensation For the three months ended September 30, 2016 and 2015, the Company recognized $49 and $30, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 72,000 and 30,000 share options granted under the 2011 Director Stock Option Plan during the three months ended September 30, 2016 and 2015, respectively. There were 45,000 share options granted under the 2005 Equity Incentive Plan during the three months ended September 30, 2015. </div>

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px"> The following is a summary of the line items impacted by the adoption of ASU 2015-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">As Originally Reported</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Adjustments for the Adoption of ASU 2015-3</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">As Currently Reported</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Prepaid expense and other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,777</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,768</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,901</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,892</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Other noncurrent assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,459</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(727</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total noncurrent assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,946</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(727</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,219</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total Assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,841</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,105</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Current maturities of long-term debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,012</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,473</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total current liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,590</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(539</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,051</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Long-term debt </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,176</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total long-term liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,762</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(197</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,565</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total Liabilities and Shareholders’ Equity </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,841</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,105</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

9443000

436000

<div> SunLink’s goodwill and intangible assets are composed of:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Goodwill </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

9443000

SSY

<div> Results for all of the businesses included in discontinued operations are presented in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" nowrap="nowrap" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,101</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,888</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(234</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">100</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,867</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,988</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Earnings (loss) before income taxes: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(64</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(594</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Sold Hospitals </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(238</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(188</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(36</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Earnings (loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(339</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(818</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Gain on Sale: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Chestatee Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,246</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,246</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(818</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense (benefit) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,634</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">283</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Earnings (Loss) from discontinued operations </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,273</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(535</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,698</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,157</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(792</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(991</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,906</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,166</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Revenues by payor were as follows for the three months ended September 30, 2016 and 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" nowrap="nowrap" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,033</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,509</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,922</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">119</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">645</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">720</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,402</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,390</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,511</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(33</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(716</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,357</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,795</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Pharmacy Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,341</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,567</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">348</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">222</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,046</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,584</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1646000

<div> Note 11. - Related Party Transactions A director of the Company and the Company’s former corporate secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $197 and $84 for legal services to these law firms in the three months ended September 30, 2016 and 2015, respectively. Included in the Company’s condensed consolidated balance sheets at September 30, 2016 and June 30, 2016 is $168 and $75, respectively, of amounts payable to these law firms. </div>

13079000 244000 <div> The components of pension expense for the three months ended September 30, 2016 and 2015, respectively, were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" nowrap="nowrap" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Pharmacy Segment Intangibles </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Trade Name (non-amortizing) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,198</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,163</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total Intangibles </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,660</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,695</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 0 <div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Long-term debt consisted of the following: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,575</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,698</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> SHPP RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,940</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,950</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Carmichael Notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,508</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Capital lease obligations and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,542</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,188</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Less unamortized debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(719</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(736</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Less current maturities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,113</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,473</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,710</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Pharmacy Segment for the three months ended September 30, 2016 and 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Three Months Ended September 30, 2016,</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">91</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">124</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">407</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">407</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(662</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(730</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">402</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">390</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">792</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Three Months Ended September 30, 2015,</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,962</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,347</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">715</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">222</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,004</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,017</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">950</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,913</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(163</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,076</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at September 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,781</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">444</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Note 6. – Revenue Recognition and Accounts Receivables The Company’s subsidiaries recognize revenues in the period in which services are provided. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received. Revenues by payor were as follows for the three months ended September 30, 2016 and 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" nowrap="nowrap" align="center"> Three Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" nowrap="nowrap" align="center">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,033</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,509</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,496</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,922</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">119</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">645</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">720</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,402</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,390</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,511</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(33</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(716</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,357</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,795</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Pharmacy Segment Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,341</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,567</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">348</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">222</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total Net Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,046</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,584</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The net revenues of the Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,698</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,157</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(792</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(991</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable - net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,906</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,166</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Pharmacy Segment for the three months ended September 30, 2016 and 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Three Months Ended September 30, 2016,</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">624</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">367</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">991</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">91</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">124</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">407</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">407</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(662</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(68</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(730</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at September 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">402</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">390</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">792</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">Three Months Ended September 30, 2015,</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Healthcare Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,962</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">385</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,347</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Continuing Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">715</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">222</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,004</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Discontinued Operations </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,017</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">950</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,913</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(163</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,076</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at September 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,781</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">444</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,225</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Note 4. – Assets held for sale On November 7, 2016, the Company’s subsidiary SunLink Healthcare Professional Property, LLC entered into an agreement to sell a medical office building in Ellijay, Georgia for approximately $4,900. The sale is subject to a number conditions, including buyer due diligence and is expected to close by December 31, 2016. The net assets to be sold of $2,136 have been reclassified as Assets Held for Sale in the September 30, 2016 Condensed Consolidated Balance Sheet. </div> 0 4

17000

250000

-839000

1000

254000

7341000

-192000

189000

173000

5455000

78000

54000

7246000

1867000

-37000

7246000

-64000

2101000

-238000

-234000

185000

2008-04-22

2017-10-22

46000

0.015

P15Y

2016-07-02

2012-07-05

Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6%

The Trace Working Capital Loan as amended provided for a revolving line of credit which expired on July 2, 2016 and was not renewed.

2012-07-05

0.020

P25Y

The prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5%

2012-10-31

72000

84 18 66 2 119000 720000 2496000 22000 2033000

32000

13000

8000

105000

35000

37000

124000

91000

33000

407000

68000

7341000

662000

5357000

33000

5390000 100 348000

197000

2 0000096793 us-gaap:ManagementMember 2016-07-01 2016-09-30 0000096793 ssy:OtherMemberMember 2016-07-01 2016-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-09-30 0000096793 ssy:PharmacySegmentMember 2016-07-01 2016-09-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2016-07-01 2016-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2016-09-30 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2016-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-07-01 2016-09-30 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2016-07-01 2016-09-30 0000096793 us-gaap:SegmentContinuingOperationsMember 2016-07-01 2016-09-30 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2016-07-01 2016-09-30 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-09-30 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-09-30 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-09-30 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-09-30 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-09-30 0000096793 ssy:MedicalOfficeBuildingMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-09-30 0000096793 ssy:AcuteCareHospitalMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-09-30 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2016-07-01 2016-09-30 0000096793 us-gaap:SubsidiariesMemberssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2016-07-01 2016-09-30 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2016-07-01 2016-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2016-07-01 2016-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2016-07-01 2016-09-30 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2016-07-01 2016-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2016-07-01 2016-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2016-07-01 2016-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2016-07-01 2016-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2016-07-01 2016-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2016-07-01 2016-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2016-07-01 2016-09-30 0000096793 us-gaap:CorporateNonSegmentMember 2016-07-01 2016-09-30 0000096793 2016-07-01 2016-09-30 0000096793 us-gaap:ManagementMember 2015-07-01 2015-09-30 0000096793 ssy:OtherMemberMember 2015-07-01 2015-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2015-07-01 2015-09-30 0000096793 ssy:PharmacySegmentMember 2015-07-01 2015-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentDiscontinuedOperationsMember 2015-07-01 2015-09-30 0000096793 us-gaap:SegmentDiscontinuedOperationsMember 2015-07-01 2015-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMemberus-gaap:SegmentContinuingOperationsMember 2015-07-01 2015-09-30 0000096793 ssy:PharmacySegmentMemberus-gaap:SegmentContinuingOperationsMember 2015-07-01 2015-09-30 0000096793 us-gaap:SegmentContinuingOperationsMember 2015-07-01 2015-09-30 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2015-07-01 2015-09-30 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2015-09-30 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2015-09-30 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2015-09-30 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2015-09-30 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2015-09-30 0000096793 ssy:TwoThousandFiveEquityIncentivePlansMember 2015-07-01 2015-09-30 0000096793 ssy:TwoThousandElevenDirectorStockOptionPlanMember 2015-07-01 2015-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:OtherSoldHospitalMember 2015-07-01 2015-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:ChestateeHospitalMember 2015-07-01 2015-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberssy:LifeSciencesAndEngineeringSegmentMember 2015-07-01 2015-09-30 0000096793 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2015-07-01 2015-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2015-07-01 2015-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2015-07-01 2015-09-30 0000096793 us-gaap:CorporateNonSegmentMember 2015-07-01 2015-09-30 0000096793 2015-07-01 2015-09-30 0000096793 2012-07-12 2014-12-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2016-09-09 2016-09-09 0000096793 ssy:ChestateeHospitalMemberssy:AssetPurchaseAgreementMember 2016-08-19 2016-08-19 0000096793 ssy:ChestateeHospitalMember 2016-08-19 2016-08-19 0000096793 us-gaap:RestatementAdjustmentMember 2016-06-30 0000096793 us-gaap:ScenarioPreviouslyReportedMember 2016-06-30 0000096793 us-gaap:ManagementMember 2016-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-06-30 0000096793 ssy:PharmacySegmentMember 2016-06-30 0000096793 ssy:MedicareLicenseMemberssy:PharmacySegmentMember 2016-06-30 0000096793 us-gaap:CustomerRelationshipsMemberssy:PharmacySegmentMember 2016-06-30 0000096793 us-gaap:TradeNamesMemberssy:PharmacySegmentMember 2016-06-30 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2016-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2016-06-30 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2016-06-30 0000096793 2016-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2015-06-30 0000096793 ssy:PharmacySegmentMember 2015-06-30 0000096793 2015-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2012-07-11 0000096793 us-gaap:ManagementMember 2016-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2016-09-30 0000096793 ssy:PharmacySegmentMember 2016-09-30 0000096793 ssy:MedicareLicenseMemberssy:PharmacySegmentMember 2016-09-30 0000096793 us-gaap:CustomerRelationshipsMemberssy:PharmacySegmentMember 2016-09-30 0000096793 us-gaap:TradeNamesMemberssy:PharmacySegmentMember 2016-09-30 0000096793 ssy:OperatingLeasesMember 2016-09-30 0000096793 ssy:InterestOnOutstandingDebtMember 2016-09-30 0000096793 us-gaap:LongTermDebtMember 2016-09-30 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMemberus-gaap:MinimumMember 2016-09-30 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2016-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MinimumMember 2016-09-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2016-09-30 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2016-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2016-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2016-09-30 0000096793 us-gaap:CorporateNonSegmentMember 2016-09-30 0000096793 2016-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2015-09-30 0000096793 ssy:PharmacySegmentMember 2015-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2015-09-30 0000096793 us-gaap:OperatingSegmentsMemberssy:PharmacySegmentMember 2015-09-30 0000096793 us-gaap:CorporateNonSegmentMember 2015-09-30 0000096793 2015-09-30 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2008-04-22 0000096793 2016-11-10 0000096793 us-gaap:SubsidiariesMemberssy:EllijayGeorgiaMemberus-gaap:SubsequentEventMember 2016-11-07 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2016-02-16 0000096793 us-gaap:SubsidiariesMemberssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2012-10-31 iso4217:USD shares pure iso4217:USD shares ssy:Hospital ssy:Segment ssy:Bed ssy:Subsidiary ssy:Areas ssy:Law_Firm

EX-101.SCH 7 ssy-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Business Operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Discontinued Operations link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Assets held for sale link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Revenue Recognition and Accounts Receivables link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Goodwill and Intangible Assets link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Financial Information by Segment link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Discontinued Operations (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Goodwill and Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Financial Information by Segment (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Business Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Discontinued Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Assets Held for Sale - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Shareholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Goodwill and Intangible Assets - Goodwill (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Long-Term Debt (Carmichael Notes) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Long-Term Debt - Summary of Line Items Impacted by the Adoption of ASU 2015-3 (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Financial Information by Segment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Financial Information by Segment - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 ssy-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ssy-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ssy-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable, Current Accounts payable Accounts Payable, Related Parties Amount payable to law firms Accounts Receivable, Gross, Current Accounts receivable (net of contractual allowances) Accrued Income Taxes, Current Income tax payable Accrued interest forgiveness. Accrued Interest Forgiveness Accrued interest forgiven Accrued Liabilities, Current Due to third party payors Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Acute care hospital. Acute Care Hospital [Member] Acute Care Hospital [Member] Additional Paid in Capital, Common Stock Additional paid-in capital Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract] Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract] Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract] Allocated Share-based Compensation Expense Share-based compensation, amount recognized Allowance for Doubtful Accounts Receivable, Current Ending balance Beginning balance Less allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Additions recognized as a reduction to revenues Allowance for Doubtful Accounts Receivable, Write-offs Accounts written off, net of recoveries Allowance for doubtful accounts. Allowance For Doubtful Accounts [Table Text Block] Summary of Allowance for Doubtful Accounts Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization expense Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Asset Purchase Agreement And Related License Agreement [Abstract] Asset purchase agreement. Asset Purchase Agreement [Member] Asset Purchase Agreement [Member] Assets Assets TOTAL ASSETS Total Assets Assets [Abstract] ASSETS Assets, Current Total current assets Total current assets Assets, Current [Abstract] Current Assets: Assets Held For Sale Disclosure [Text Block] Assets Held For Sale Disclosure [Text Block] Assets held for sale Assets, Noncurrent [Abstract] Noncurrent Assets: Disposal Group, Including Discontinued Operation, Assets, Current Current assets held for sale Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Table] Business And Organization [Table] Business And Organization [Table] Capital Lease Obligations Capital lease obligations and other Carmichael. Carmichael's Cashway Pharmacy, Note [Member] Carmichael Notes [Member] Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents End of Period Cash and Cash Equivalents Beginning of Period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in Cash and Cash Equivalents Chestatee hospital. Chestatee Hospital [Member] Chestatee Hospital [Member] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitment, Contingency And Related Party Transactions [Abstract] Commitments and Contingencies Commitment and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, No Par Value Common shares, without par value Common Stock, Shares, Issued Common shares, issued Common Stock, Shares, Outstanding Common shares, outstanding Common Stock, Value, Issued Common Shares, without par value: Issued and outstanding, 9,444 shares at September 30, 2016 and at June 30, 2016 Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Earnings (Loss) Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Contractual Obligation Contractual obligations, commitments and contingencies Contractual Obligation, Due after Fifth Year Payments due in 5+ years Contractual Obligation, Due in Fourth Year Payments due in 4 years Contractual Obligation, Due in Second Year Payments due in 2 years Contractual Obligation, Due in Third Year Payments due in 3 years Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of Contractual Obligations, Commitments and Contingencies Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year Payments due in 1 year Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Cost of Goods Sold Cost of goods sold Cost of Services Purchased services Costs and Expenses [Abstract] Costs and Expenses Current Federal Tax Expense (Benefit) Federal tax expense (benefit) Current Fiscal Year End Date Current Fiscal Year End Date Current State and Local Tax Expense (Benefit) State tax expense (benefit) Customer Relationships [Member] Customer Relationships [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Floating rate of interest, spread Debt Instrument, Description of Variable Rate Basis Debt instrument description Debt Instrument, Face Amount Loan agreement amount Debt Instrument, Interest Rate, Effective Percentage Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated Debt Instrument, Interest Rate, Stated Percentage Interest rate percentage Debt Instrument, Issuance Date Date of loan agreement Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Note due date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Periodic Payment Principal and interest payment Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Debt instrument maturity period Deferred Tax Assets, Net of Valuation Allowance Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Current Deferred income tax asset Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred income tax asset Deferred Tax Assets, Valuation Allowance Deferred income tax valuation allowance Deferred Tax Liabilities, Net, Noncurrent Deferred income tax liability Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Amortization of prior service cost Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan, Expected Return on Plan Assets Expected return on assets Defined Benefit Plan, Interest Cost Interest Cost Defined Benefit Plans, Estimated Future Employer Contributions in Current Fiscal Year Expected contribution to pension plan during the remaining fiscal year Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain on Sale Discontinued operation income loss from discontinued operation before income tax. Discontinued Operation Income Loss From Discontinued Operation Before Income Tax [Abstract] Earnings (loss) before income taxes: Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Earnings (Loss) before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Earnings (Loss) from discontinued operations Earnings from Discontinued Operations, net of tax Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period Income tax expense (benefit) Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Including Discontinued Operation, Assets, Noncurrent Noncurrent assets held for sale Disposal Group, Including Discontinued Operation, Consideration Consideration for sale of medical office building Disposal group including discontinued operation revenue net of expenses. Disposal Group Including Discontinued Operation Revenue Net Of Expenses Net revenues Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Disposal Group Name [Domain] Disposal Group Name [Domain] Document and entity information Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings (loss) per share continuing operations. Earnings Loss Per Share Continuing Operations [Abstract] Continuing Operations: Earnings (loss) per share discontinued operations. Earnings Loss Per Share Discontinued Operations [Abstract] Discontinued Operations: Earnings Per Share [Abstract] Net Earnings (Loss): Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Ellijay Georgia [Member]. Ellijay Georgia Member Ellijay Georgia Member Employee-related Liabilities, Current Accrued payroll and related taxes Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Extinguishment of Debt, Amount Notes paid Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Revenue from Financial and Health Care Services Financial And Healthcare Services Revenue Net revenues Operating revenues (net of contractual allowances) Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Gain (Loss) on Disposition of Oil and Gas and Timber Property [Abstract] Gain on Sale: Gain (Loss) on Extinguishment of Debt Gain on extinguishment of debt Gain (Loss) on Disposition of Assets for Financial Service Operations Gain on sale of assets Goodwill Goodwill Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Goodwill [Line Items] Goodwill [Line Items] Healthcare facilities segment. Healthcare Facilities Segment [Member] Healthcare Facilities Segment [Member] Health Care Organization, Patient Service Revenue Provision for Bad Debts Less provision for bad debts of Healthcare Facilities Segment Provision for doubtful accounts Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Health Care Organizations [Abstract] Health Care Organizations [Abstract] Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Loss from Continuing Operations before income taxes Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Loss from Continuing Operations Income (Loss) from Continuing Operations, Per Basic Share Basic Income (Loss) from Continuing Operations, Per Diluted Share Diluted Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Basic Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Diluted Income Statement [Abstract] Income Statement [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid, Net Income taxes Income Tax Expense (Benefit) Income tax expense (benefit) Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Intangible Assets, Gross (Excluding Goodwill) Finite and Indefinite-Lived Intangible Assets, Gross Intangible Assets, Net (Excluding Goodwill) Intangible assets - net Total Interest Expense Interest expense - net Interest On Outstanding Debt [Member] Interest On Outstanding Debt [Member] Interest on Outstanding Debt [Member] Interest Paid Interest Inventory, Net Inventory Labor and Related Expense Salaries, wages and benefits Legal Entity [Axis] Legal Entity [Axis] Liabilities and Equity Total Liabilities and Shareholders' Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current Total current liabilities Total current liabilities Liabilities, Current [Abstract] Current liabilities: Liabilities, Noncurrent Total long-term liabilities Total long-term liabilities Liabilities, Noncurrent [Abstract] Long-Term Liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current Current liabilities held for sale Life sciences and engineering segment. Life Sciences And Engineering Segment [Member] Life Sciences and Engineering [Member] Long-term Line of Credit Line of credit, outstanding borrowings Line of Credit Facility, Borrowing Capacity, Description Line of credit, loan description Line of Credit Facility, Expiration Date Working capital expiration date Line of Credit Facility, Initiation Date Working Capital Loan Agreement, initiation date Loans Payable Indebtedness under the loan RDA Loan Loans payable modification and waiver. Loans Payable Modification and Waiver Loans payable modification or waiver Long-term Debt Total Total Long-term Debt, Current Maturities Current maturities of long-term debt Less current maturities Long-term Debt [Member] Long-Term Debt [Member] Long-term Debt, Excluding Current Maturities Long-term debt Total Long-term debt, excluding current maturities, total Long-term Debt [Text Block] Long-Term Debt Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long term obligations. Long Term Obligations [Text Block] Summary of Long-Term Debt Managed care and other insurers. Managed Care And Other Insurers [Member] Managed Care & Other Insurance [Member] Management [Member] Management [Member] Medicaid. Medicaid [Member] Medicaid [Member] Medical office building. Medical Office Building [Member] Medical Office Building [Member] Medicare license. Medicare License [Member] Medicare License [Member] EX-101.PRE 11 ssy-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 10, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	SSY
Entity Registrant Name	SUNLINK HEALTH SYSTEMS INC
Entity Central Index Key	0000096793
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,443,408

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Current Assets:
Cash and cash equivalents	$ 12,801	$ 3,261
Receivables - net	5,906	6,166
Inventory	2,323	2,612
Deferred income tax asset	0	624
Current assets held for sale	0	2,461
Prepaid expense and other assets	3,008	2,768
Total current assets	24,038	17,892
Property, plant and equipment, at cost	31,378	33,914
Less accumulated depreciation	20,686	20,920
Property, plant and equipment - net	10,692	12,994
Noncurrent Assets:
Intangible assets - net	2,660	2,695
Goodwill	461	461
Deferred income tax asset	0	1,698
Noncurrent assets held for sale	2,136	7,633
Other noncurrent assets	676	732
Total noncurrent assets	5,933	13,219
TOTAL ASSETS	40,663	44,105
Current liabilities:
Accounts payable	2,160	3,391
Current maturities of long-term debt	7,113	7,473
Accrued payroll and related taxes	2,347	2,872
Due to third party payors	1,042	1,883
Income tax payable	81	2
Current liabilities held for sale	0	2,745
Other accrued expenses	1,621	1,685
Total current liabilities	14,364	20,051
Long-Term Liabilities
Long-term debt	1,710	2,979
Deferred income tax liability	378	0
Noncurrent liability for professional liability risks	1,131	1,161
Other noncurrent liabilities	519	425
Total long-term liabilities	3,738	4,565
Commitment and Contingencies
Shareholders' Equity
Preferred Shares, authorized and unissued, 2,000 shares	0	0
Common Shares, without par value: Issued and outstanding, 9,444 shares at September 30, 2016 and at June 30, 2016	4,722	4,722
Additional paid-in capital	13,588	13,539
Retained earnings	4,671	1,648
Accumulated other comprehensive loss	(420)	(420)
Total Shareholders' Equity	22,561	19,489
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 40,663	$ 44,105

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Jun. 30, 2016
Statement of Financial Position [Abstract]
Preferred shares, authorized	2,000,000	2,000,000
Preferred shares, unissued	2,000,000	2,000,000
Common shares, without par value
Common shares, issued	9,444,000	9,444,000
Common shares, outstanding	9,444,000	9,444,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Operating revenues (net of contractual allowances)	$ 13,079	$ 17,300
Less provision for bad debts of Healthcare Facilities Segment	33	716
Net revenues	13,046	16,584
Costs and Expenses
Cost of goods sold	4,636	4,597
Salaries, wages and benefits	5,845	8,317
Provision for bad debts of Specialty Pharmacy Segment	91	222
Supplies	436	916
Purchased services	708	869
Other operating expenses	1,710	2,201
Rent and lease expense	129	201
Depreciation and amortization	444	427
Operating Loss	(953)	(1,166)
Other Income, (Expense):
Gain on sale of assets	22	1
Gain on extinguishment of debt	46	0
Interest expense - net	(221)	(217)
Loss from Continuing Operations before income taxes	(1,106)	(1,382)
Income tax expense (benefit)	144	(249)
Loss from Continuing Operations	(1,250)	(1,133)
Earnings from Discontinued Operations, net of tax	4,273	(535)
Net Earnings (Loss)	3,023	(1,668)
Other comprehensive income	0	0
Comprehensive Earnings (Loss)	$ 3,023	$ (1,668)
Continuing Operations:
Basic	$ (0.13)	$ (0.12)
Diluted	(0.13)	(0.12)
Discontinued Operations:
Basic	0.45	(0.06)
Diluted	0.45	(0.06)
Net Earnings (Loss):
Basic	0.32	(0.18)
Diluted	$ 0.32	$ (0.18)
Weighted-Average Common Shares Outstanding:
Basic	9,443	9,443
Diluted	9,443	9,443

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Statement of Cash Flows [Abstract]
Net Cash Used in Operating Activities	$ (3,190)	$ (815)
Cash Flows from Investing Activities:
Proceeds from sale of Chestatee	14,620	0
Expenditures for property, plant and equipment - continuing operations	(244)	(463)
Expenditures for property, plant and equipment - discontinued operations	0	(15)
Net Cash Provided by (Used in) Investing Activities	14,376	(478)
Cash Flows from Financing Activities:
Payments on long-term debt - continuing operation	(1,646)	(175)
Payments on long-term debt - discontinued operations	0	0
Net Cash Used in Financing Activities	(1,646)	(175)
Net increase (decrease) in Cash and Cash Equivalents	9,540	(1,468)
Cash and Cash Equivalents Beginning of Period	3,261	5,974
Cash and Cash Equivalents End of Period	12,801	4,506
Cash Paid (Received) for:
Interest	206	200
Income taxes	$ 33	$ 76

XML 17 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation	3 Months Ended
Basis of Presentation	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1. –Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of September 30, 2016 and for the three month periods ended September 30, 2016 and 2015 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2016 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2016, filed with the SEC on September 30, 2016. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three month period ended September 30, 2016 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Business Operations

3 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Operations

Note 2. – Business Operations

Business Operations

SunLink owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:

•

The Healthcare Facilities Segments, which is composed of:

•

A subsidiary which owns and operates an 84-licensed-bed, acute care hospital, which includes an 18-bed GPU, and a 66-bed nursing home.

•

Two separate subsidiaries which own medical buildings, which are leased to unaffiliated healthcare providers.

•

A subsidiary which owns a closed hospital building and a medical office building which it currently rents office space to one unaffiliated healthcare provider.

•

The Specialty Pharmacy Segment, which is composed of four operational areas:

•

Retail pharmacy products and services, all of which are conducted in rural markets;

•

Institutional pharmacy services;

•

Specialty pharmacy services; and

•

Durable medical equipment.

Our Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Discontinued Operations

3 Months Ended

Sep. 30, 2016

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Note 3. – Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended
	September 30,
	2016			2015
Net Revenues:
Chestatee Hospital	$	2,101		$	3,888
Other Sold Hospitals		(234	)		100

	$	1,867		$	3,988

Earnings (loss) before income taxes:
Chestatee Hospital	$	(64	)	$	(594	)
Other Sold Hospitals		(238	)		(188	)
Life sciences and engineering		(37	)		(36	)

Earnings (loss) before income taxes		(339	)		(818	)

Gain on Sale:
Chestatee Hospital		7,246			0

Earnings (Loss) before income taxes		7,246			(818	)


Income tax expense (benefit)		2,634			283


Earnings (Loss) from discontinued operations	$	4,273		$	(535	)

The components of pension expense for the three months ended September 30, 2016 and 2015, respectively, were as follows:


	Three Months Ended
	September 30,
	2016			2015
Interest Cost	$	13		$	16
Expected return on assets		(8	)		(8	)
Amortization of prior service cost		32			28

Net pension expense	$	37		$	36

SunLink contributed $35 to the plan in the three months ended September 30, 2016 and expects to contribute an additional $105 during the last three quarter of the fiscal year ending June 30, 2017.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Assets held for sale	3 Months Ended
Assets held for sale	Sep. 30, 2016
Text Block [Abstract]
Assets held for sale	Note 4. – Assets held for sale On November 7, 2016, the Company’s subsidiary SunLink Healthcare Professional Property, LLC entered into an agreement to sell a medical office building in Ellijay, Georgia for approximately $4,900. The sale is subject to a number conditions, including buyer due diligence and is expected to close by December 31, 2016. The net assets to be sold of $2,136 have been reclassified as Assets Held for Sale in the September 30, 2016 Condensed Consolidated Balance Sheet.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Shareholders' Equity	3 Months Ended
Shareholders' Equity	Sep. 30, 2016
Equity [Abstract]
Shareholders' Equity	Note 5. – Shareholders’ Equity *Tax Benefits Protection Rights Plan* On September 29, 2016, SunLink entered into a Tax Benefits Preservation Rights Plan (the “Tax Benefits Protection Rights Plan”). Effective September 29, 2016, the Board declared a dividend in the form of one preferred stock purchase right for each of the Company’s issued and outstanding common shares. The purpose of the Tax Benefits Protection Rights Plan is to diminish the risk that the Company’s ability to use its net operating losses and certain other tax assets to reduce potential future federal income tax obligations would become subject to limitations by reason of the Company experiencing an “ownership change,” as defined in Section 382 of the Code. *Stock-Based Compensation* For the three months ended September 30, 2016 and 2015, the Company recognized $49 and $30, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 72,000 and 30,000 share options granted under the 2011 Director Stock Option Plan during the three months ended September 30, 2016 and 2015, respectively. There were 45,000 share options granted under the 2005 Equity Incentive Plan during the three months ended September 30, 2015.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables

3 Months Ended

Sep. 30, 2016

Receivables [Abstract]

Revenue Recognition and Accounts Receivables

Note 6. – Revenue Recognition and Accounts Receivables

Revenues by payor were as follows for the three months ended September 30, 2016 and 2015:


	Three Months Ended
	September 30,
	2016			2015
Healthcare Facilities Segment:
Medicare	$	2,033		$	3,509
Medicaid		2,496			2,922
Self-pay		119			645
Managed Care & Other Insurance		720			2,402
Other		22			33

Revenues before provision for doubtful accounts		5,390			9,511
Provision for doubtful accounts		(33	)		(716	)

Healthcare Facilities Segment Net Revenues		5,357			8,795
Pharmacy Segment Net Revenues		7,341			7,567
Other Revenues		348			222

Total Net Revenues	$	13,046		$	16,584

Summary information for accounts receivable is as follows:


	September 30,			June 30,
	2016			2016
Accounts receivable (net of contractual allowances)	$	6,698		$	7,157
Less allowance for doubtful accounts		(792	)		(991	)

Patient accounts receivable - net	$	5,906		$	6,166


Three Months Ended September 30, 2016,	Healthcare Facilities			Pharmacy			Total
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		33			91			124
Discontinued Operations		407			—			407
Accounts written off, net of recoveries		(662	)		(68	)		(730	)

Balance at September 30, 2016	$	402		$	390		$	792


Three Months Ended September 30, 2015,	Healthcare Facilities			Pharmacy			Total
Balance at July 1, 2015	$	4,962		$	385		$	5,347
Additions recognized as a reduction to revenues:
Continuing Operations		715			222			1,004
Discontinued Operations		1,017			—			950
Accounts written off, net of recoveries		(1,913	)		(163	)		(2,076	)

Balance at September 30, 2015	$	4,781		$	444		$	5,225

XML 23 R12.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets

3 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Note 7. - Goodwill and Intangible Assets

SunLink’s goodwill and intangible assets are composed of:


	September 30,		June 30,
	2016		2016

Pharmacy Segment Goodwill	$	461	$	461

Intangibles consist of the following, net of amortization:


	September 30,			June 30,
	2016			2016

Pharmacy Segment Intangibles
Trade Name (non-amortizing)		2,000			2,000
Customer Relationships		1,089			1,089
Medicare License		769			769

		3,858			3,858
Accumulated Amortization		(1,198	)		(1,163	)


Total Intangibles	$	2,660		$	2,695

Amortization expense was $36 and $36 for the three months ended September 30, 2016 and 2015, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Long-Term Debt

3 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Long-Term Debt

Note 8. –Long-Term Debt

Long-term debt consisted of the following:


	September 30,			June 30,
	2016			2016
Trace RDA Loan	$	7,575		$	7,698
SHPP RDA Loan		1,940			1,950
Carmichael Notes		0			1,508
Capital lease obligations and other		27			32

Total		9,542			11,188
Less unamortized debt issuance costs		(719	)		(736	)
Less current maturities		(7,113	)		(7,473	)

	$	1,710		$	2,979

The following is a summary of the line items impacted by the adoption of ASU 2015-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet:


	As Originally Reported		Adjustments for the Adoption of ASU 2015-3			As Currently Reported
Prepaid expense and other current assets	$	2,777	$	(9	)	$	2,768
Total current assets	$	17,901	$	(9	)	$	17,892
Other noncurrent assets	$	1,459	$	(727	)	$	732
Total noncurrent assets	$	13,946	$	(727	)	$	13,219
Total Assets	$	44,841	$	(736	)	$	44,105
Current maturities of long-term debt	$	8,012	$	(539	)	$	7,473
Total current liabilities	$	20,590	$	(539	)	$	20,051
Long-term debt	$	3,176	$	(197	)	$	2,979
Total long-term liabilities	$	4,762	$	(197	)	$	4,565
Total Liabilities and Shareholders’ Equity	$	44,841	$	(736	)	$	44,105

XML 25 R14.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. – Income Taxes Income tax expense of $144 ($210 federal tax expense and $66 state tax benefit) and income tax benefit of $249 ($229 federal tax benefit and $20 state tax benefit) was recorded for continuing operations for the three months ended September 30, 2016 and 2015, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. At September 30, 2016, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $10,818 against the deferred tax asset so that there is a net deferred income tax liability of $378 at September 30, 2016. A $378 net deferred long-term income tax liability is recorded at September 30, 2016 as required under interim reporting guidance of ASC 740-270. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at September 30, 2016 that all the deferred tax assets should have a full valuation allowances of the net deferred income tax assets was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Facilities Segment businesses operate. The deferred income tax liability of $378 at September 30, 2016 will be adjusted quarterly as required under the requirements for interim reporting guidance of ASC 740-270. For Federal income tax purposes, at September 30, 2016, the Company had approximately $10,000 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 10. – Commitments and Contingencies

Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	7,637	$	461	$	519
2 years		51		368		104
3 years		47		303		101
4 years		49		255		98
5+ years		1,758		74		746

	$	9,542	$	1,461	$	1,568

XML 27 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions	3 Months Ended
Related Party Transactions	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. - Related Party Transactions A director of the Company and the Company’s former corporate secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $197 and $84 for legal services to these law firms in the three months ended September 30, 2016 and 2015, respectively. Included in the Company’s condensed consolidated balance sheets at September 30, 2016 and June 30, 2016 is $168 and $75, respectively, of amounts payable to these law firms.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Financial Information by Segment

3 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Financial Information by Segment

Note 12. - Financial Information by Segment


	Healthcare						Corporate
	Facilities			Pharmacy			and Other			Total
As of and for the three months ended September 30, 2016
Net revenues from external customers	$	5,455		$	7,341		$	250		$	13,046
Operating profit (loss)		78			(192	)		(839	)		(953	)
Depreciation and amortization		173			254			17			444
Assets		13,686			11,420			15,557			40,663
Expenditures for property, plant and equipment		54			189			1			244

As of and for the three months ended September 30, 2015
Net revenues from external customers	$	8,795		$	7,567		$	222		$	16,584
Operating profit (loss)		(498	)		(79	)		(589	)		(1,166	)
Depreciation and amortization		181			198			48			427
Assets		27,080			11,855			16,360			55,295
Expenditures for property, plant and equipment		35			428			0			463

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

3 Months Ended

Sep. 30, 2016

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended
	September 30,
	2016			2015
Net Revenues:
Chestatee Hospital	$	2,101		$	3,888
Other Sold Hospitals		(234	)		100

	$	1,867		$	3,988

Earnings (loss) before income taxes:
Chestatee Hospital	$	(64	)	$	(594	)
Other Sold Hospitals		(238	)		(188	)
Life sciences and engineering		(37	)		(36	)

Earnings (loss) before income taxes		(339	)		(818	)

Gain on Sale:
Chestatee Hospital		7,246			0

Earnings (Loss) before income taxes		7,246			(818	)


Income tax expense (benefit)		2,634			283


Earnings (Loss) from discontinued operations	$	4,273		$	(535	)

Components of Pension Expense

The components of pension expense for the three months ended September 30, 2016 and 2015, respectively, were as follows:


	Three Months Ended
	September 30,
	2016			2015
Interest Cost	$	13		$	16
Expected return on assets		(8	)		(8	)
Amortization of prior service cost		32			28

Net pension expense	$	37		$	36

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables (Tables)

3 Months Ended

Sep. 30, 2016

Receivables [Abstract]

Summary of Revenues

Revenues by payor were as follows for the three months ended September 30, 2016 and 2015:


	Three Months Ended
	September 30,
	2016			2015
Healthcare Facilities Segment:
Medicare	$	2,033		$	3,509
Medicaid		2,496			2,922
Self-pay		119			645
Managed Care & Other Insurance		720			2,402
Other		22			33

Revenues before provision for doubtful accounts		5,390			9,511
Provision for doubtful accounts		(33	)		(716	)

Healthcare Facilities Segment Net Revenues		5,357			8,795
Pharmacy Segment Net Revenues		7,341			7,567
Other Revenues		348			222

Total Net Revenues	$	13,046		$	16,584

Summary Information for Accounts Receivable

Summary information for accounts receivable is as follows:


	September 30,			June 30,
	2016			2016
Accounts receivable (net of contractual allowances)	$	6,698		$	7,157
Less allowance for doubtful accounts		(792	)		(991	)

Patient accounts receivable - net	$	5,906		$	6,166

Summary of Allowance for Doubtful Accounts


Three Months Ended September 30, 2016,	Healthcare Facilities			Pharmacy			Total
Balance at July 1, 2016	$	624		$	367		$	991
Additions recognized as a reduction to revenues:
Continuing Operations		33			91			124
Discontinued Operations		407			—			407
Accounts written off, net of recoveries		(662	)		(68	)		(730	)

Balance at September 30, 2016	$	402		$	390		$	792


Three Months Ended September 30, 2015,	Healthcare Facilities			Pharmacy			Total
Balance at July 1, 2015	$	4,962		$	385		$	5,347
Additions recognized as a reduction to revenues:
Continuing Operations		715			222			1,004
Discontinued Operations		1,017			—			950
Accounts written off, net of recoveries		(1,913	)		(163	)		(2,076	)

Balance at September 30, 2015	$	4,781		$	444		$	5,225

XML 31 R20.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Tables)

3 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

SunLink’s goodwill and intangible assets are composed of:


	September 30,		June 30,
	2016		2016

Pharmacy Segment Goodwill	$	461	$	461

Intangible Assets

Intangibles consist of the following, net of amortization:


	September 30,			June 30,
	2016			2016

Pharmacy Segment Intangibles
Trade Name (non-amortizing)		2,000			2,000
Customer Relationships		1,089			1,089
Medicare License		769			769

		3,858			3,858
Accumulated Amortization		(1,198	)		(1,163	)


Total Intangibles	$	2,660		$	2,695

XML 32 R21.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Tables)

3 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Summary of Long-Term Debt

Long-term debt consisted of the following:


	September 30,			June 30,
	2016			2016
Trace RDA Loan	$	7,575		$	7,698
SHPP RDA Loan		1,940			1,950
Carmichael Notes		0			1,508
Capital lease obligations and other		27			32

Total		9,542			11,188
Less unamortized debt issuance costs		(719	)		(736	)
Less current maturities		(7,113	)		(7,473	)

	$	1,710		$	2,979

Summary of Line Items Impacted by the Adoption of ASU 2015-3

The following is a summary of the line items impacted by the adoption of ASU 2015-3 in the Company’s June 30, 2016 accompanying condensed consolidated balance sheet:


	As Originally Reported		Adjustments for the Adoption of ASU 2015-3			As Currently Reported
Prepaid expense and other current assets	$	2,777	$	(9	)	$	2,768
Total current assets	$	17,901	$	(9	)	$	17,892
Other noncurrent assets	$	1,459	$	(727	)	$	732
Total noncurrent assets	$	13,946	$	(727	)	$	13,219
Total Assets	$	44,841	$	(736	)	$	44,105
Current maturities of long-term debt	$	8,012	$	(539	)	$	7,473
Total current liabilities	$	20,590	$	(539	)	$	20,051
Long-term debt	$	3,176	$	(197	)	$	2,979
Total long-term liabilities	$	4,762	$	(197	)	$	4,565
Total Liabilities and Shareholders’ Equity	$	44,841	$	(736	)	$	44,105

- Definition

Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	7,637	$	461	$	519
2 years		51		368		104
3 years		47		303		101
4 years		49		255		98
5+ years		1,758		74		746

	$	9,542	$	1,461	$	1,568

XML 34 R23.htm IDEA: XBRL DOCUMENT

Financial Information by Segment (Tables)

3 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

Segment Information


	Healthcare						Corporate
	Facilities			Pharmacy			and Other			Total
As of and for the three months ended September 30, 2016
Net revenues from external customers	$	5,455		$	7,341		$	250		$	13,046
Operating profit (loss)		78			(192	)		(839	)		(953	)
Depreciation and amortization		173			254			17			444
Assets		13,686			11,420			15,557			40,663
Expenditures for property, plant and equipment		54			189			1			244

As of and for the three months ended September 30, 2015
Net revenues from external customers	$	8,795		$	7,567		$	222		$	16,584
Operating profit (loss)		(498	)		(79	)		(589	)		(1,166	)
Depreciation and amortization		181			198			48			427
Assets		27,080			11,855			16,360			55,295
Expenditures for property, plant and equipment		35			428			0			463

XML 35 R24.htm IDEA: XBRL DOCUMENT

Business Operations - Additional Information (Detail)	3 Months Ended
Business Operations - Additional Information (Detail)	Sep. 30, 2016 Segment Bed Subsidiary Areas
Business And Organization [Line Items]
Number of segments \| Segment	2
Healthcare Facilities Segment [Member]
Business And Organization [Line Items]
Number of bed in nursing home owned and operated by subsidiary	100
Healthcare Facilities Segment [Member] \| Acute Care Hospital [Member]
Business And Organization [Line Items]
Number of licensed-bed owned and operated by a subsidiary	84
Number of bed in geriatric psychiatric units owned and operated by subsidiary	18
Number of bed in nursing home owned and operated by subsidiary	66
Healthcare Facilities Segment [Member] \| Medical Office Building [Member]
Business And Organization [Line Items]
Number of subsidiaries who own medical buildings \| Subsidiary	2
Specialty Pharmacy Segment [Member]
Business And Organization [Line Items]
Number of operational areas \| Areas	4

XML 36 R25.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Schedule of Discontinued Operations (Detail) - USD ($) $ in Thousands		3 Months Ended
	Aug. 19, 2016	Sep. 30, 2016	Sep. 30, 2015
Earnings (loss) before income taxes:
Earnings (Loss) before income taxes		$ (339)	$ (818)
Gain on Sale:
Income tax expense (benefit)		2,634	283
Earnings (Loss) from discontinued operations		4,273	(535)
Chestatee Hospital [Member]
Earnings (loss) before income taxes:
Earnings (Loss) before income taxes	$ 7,246
Discontinued Operations, Disposed of by Sale [Member]
Net Revenues:
Net revenues		1,867	3,988
Gain on Sale:
Gain on Sale		7,246	(818)
Discontinued Operations, Disposed of by Sale [Member] \| Chestatee Hospital [Member]
Net Revenues:
Net revenues		2,101	3,888
Earnings (loss) before income taxes:
Earnings (Loss) before income taxes		(64)	(594)
Gain on Sale:
Gain on Sale		7,246	0
Discontinued Operations, Disposed of by Sale [Member] \| Other Sold Hospitals [Member]
Net Revenues:
Net revenues		(234)	100
Earnings (loss) before income taxes:
Earnings (Loss) before income taxes		(238)	(188)
Discontinued Operations, Disposed of by Sale [Member] \| Life Sciences and Engineering [Member]
Earnings (loss) before income taxes:
Earnings (Loss) before income taxes		$ (37)	$ (36)

XML 37 R26.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Additional Information (Detail) $ in Thousands		3 Months Ended		30 Months Ended
	Aug. 19, 2016 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2014 Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale		$ 14,620	$ 0
Earnings (Loss) before income taxes		(339)	$ (818)
Number of Hospitals Sold \| Hospital				3
Chestatee Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Earnings (Loss) before income taxes	$ 7,246
Chestatee Hospital [Member] \| Asset Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale	$ 15,000
Life Sciences and Engineering [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to pension plan		35
Expected contribution to pension plan during the remaining fiscal year		$ 105

XML 38 R27.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Components of Pension Expense (Detail) - Life Sciences and Engineering [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Interest Cost	$ 13	$ 16
Expected return on assets	(8)	(8)
Amortization of prior service cost	32	28
Net pension expense	$ 37	$ 36

XML 39 R28.htm IDEA: XBRL DOCUMENT

Assets Held for Sale - Additional Information (Detail) - USD ($) $ in Thousands	Nov. 07, 2016	Sep. 30, 2016	Jun. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncurrent assets held for sale		$ 2,136	$ 7,633
Ellijay Georgia Member \| Subsequent Events [Member] \| Subsidiaries [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration for sale of medical office building	$ 4,900

XML 40 R29.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, amount recognized	$ 49	$ 30
2011 Director Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	72,000	30,000
2005 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted		45,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	$ 13,079	$ 17,300
Provision for doubtful accounts	(33)	(716)
Net revenues	13,046	16,584
Healthcare Facilities Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	5,390	9,511
Provision for doubtful accounts	(33)	(716)
Net revenues	5,357	8,795
Healthcare Facilities Segment [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	2,033	3,509
Healthcare Facilities Segment [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	2,496	2,922
Healthcare Facilities Segment [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	119	645
Healthcare Facilities Segment [Member] \| Managed Care & Other Insurance [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	720	2,402
Healthcare Facilities Segment [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	22	33
Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	7,341	7,567
Other Member [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net revenues	$ 348	$ 222

XML 42 R31.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Jun. 30, 2015
Receivables [Abstract]
Accounts receivable (net of contractual allowances)	$ 6,698	$ 7,157
Less allowance for doubtful accounts	(792)	(991)	$ (5,225)	$ (5,347)
Patient accounts receivable - net	$ 5,906	$ 6,166

XML 43 R32.htm IDEA: XBRL DOCUMENT

Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	$ 991	$ 5,347
Accounts written off, net of recoveries	(730)	(2,076)
Ending balance	792	5,225
Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	124	1,004
Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	407	950
Healthcare Facilities Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	624	4,962
Accounts written off, net of recoveries	(662)	(1,913)
Ending balance	402	4,781
Healthcare Facilities Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	33	715
Healthcare Facilities Segment [Member] \| Discontinued Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	407	1,017
Pharmacy Segment [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Beginning balance	367	385
Accounts written off, net of recoveries	(68)	(163)
Ending balance	390	444
Pharmacy Segment [Member] \| Continuing Operations [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Additions recognized as a reduction to revenues	$ 91	$ 222

XML 44 R33.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Goodwill (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Goodwill [Line Items]
Goodwill	$ 461	$ 461
Pharmacy Segment [Member]
Goodwill [Line Items]
Goodwill	$ 461	$ 461

XML 45 R34.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Indefinite-lived Intangible Assets [Line Items]
Total	$ 2,660	$ 2,695
Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite and Indefinite-Lived Intangible Assets, Gross	3,858	3,858
Accumulated Amortization	(1,198)	(1,163)
Total	2,660	2,695
Trade Name [Member] \| Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	2,000	2,000
Customer Relationships [Member] \| Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,089	1,089
Medicare License [Member] \| Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 769	$ 769

XML 46 R35.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 36	$ 36

XML 47 R36.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Feb. 16, 2016
Debt Instrument [Line Items]
Capital lease obligations and other	$ 27	$ 32
Total	9,542	11,188
Total	9,542	11,188
Less unamortized debt issuance costs	(719)	(736)
Less current maturities	(7,113)	(7,473)
Total Long-term debt, excluding current maturities, total	1,710	2,979
Trace RDA Loan [Member]
Debt Instrument [Line Items]
RDA Loan	7,575	7,698
SHPP RDA Loan [Member]
Debt Instrument [Line Items]
RDA Loan	1,940	1,950
Carmichael Notes [Member]
Debt Instrument [Line Items]
Carmichael Notes	$ 0	$ 1,508	$ 1,255

XML 48 R37.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) - Trace RDA Loan [Member] - USD ($)	3 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Jul. 11, 2012
Debt Instrument [Line Items]
Working Capital Loan Agreement, initiation date	Jul. 05, 2012
Debt instrument maturity period	15 years
Floating rate of interest, spread	1.50%
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	6.00%
Debt instrument description	Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6%
Line of credit, outstanding borrowings		$ 0
Working capital expiration date	Jul. 02, 2016
Line of credit, loan description	The Trace Working Capital Loan as amended provided for a revolving line of credit which expired on July 2, 2016 and was not renewed.
Loans payable modification or waiver	$ 0	0
Indebtedness under the loan	$ 7,575,000	$ 7,698,000
Minimum [Member]
Debt Instrument [Line Items]
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	6.00%
Mortgages [Member]
Debt Instrument [Line Items]
Date of loan agreement	Jul. 05, 2012
Loan agreement amount			$ 9,975,000

XML 49 R38.htm IDEA: XBRL DOCUMENT

Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) - SHPP RDA Loan [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Oct. 31, 2012
Debt Instrument [Line Items]
Debt instrument maturity period	25 years
Floating rate of interest, spread	2.00%
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	5.50%
Debt instrument description	The prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5%
Minimum [Member]
Debt Instrument [Line Items]
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	5.00%
Subsidiaries [Member]
Debt Instrument [Line Items]
Loan agreement amount		$ 2,100
Date of loan agreement	Oct. 31, 2012

XML 50 R39.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Carmichael Notes) - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
	Sep. 09, 2016	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Feb. 16, 2016	Apr. 22, 2008
Debt Instrument [Line Items]
Gain on extinguishment of debt		$ 46	$ 0
Carmichael Notes [Member]
Debt Instrument [Line Items]
Loan agreement amount						$ 3,000
Interest rate percentage						8.00%
Date of loan agreement		Apr. 22, 2008
Principal and interest payment		$ 185
Carmichael Notes		$ 0		$ 1,508	$ 1,255
Note due date		Oct. 22, 2017
Notes paid	$ 1,508
Accrued interest forgiven	$ 46
Gain on extinguishment of debt		$ 46

XML 51 R40.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Summary of Line Items Impacted by the Adoption of ASU 2015-3 (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expense and other current assets	$ 3,008	$ 2,768
Total current assets	24,038	17,892
Other noncurrent assets	676	732
Total noncurrent assets	5,933	13,219
Total Assets	40,663	44,105	$ 55,295
Current maturities of long-term debt	7,113	7,473
Total current liabilities	14,364	20,051
Long-term debt	1,710	2,979
Total long-term liabilities	3,738	4,565
Total Liabilities and Shareholders' Equity	$ 40,663	44,105
As Originally Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expense and other current assets		2,777
Total current assets		17,901
Other noncurrent assets		1,459
Total noncurrent assets		13,946
Total Assets		44,841
Current maturities of long-term debt		8,012
Total current liabilities		20,590
Long-term debt		3,176
Total long-term liabilities		4,762
Total Liabilities and Shareholders' Equity		44,841
Adjustments for the Adoption of ASU 2015-3 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expense and other current assets		(9)
Total current assets		(9)
Other noncurrent assets		(727)
Total noncurrent assets		(727)
Total Assets		(736)
Current maturities of long-term debt		(539)
Total current liabilities		(539)
Long-term debt		(197)
Total long-term liabilities		(197)
Total Liabilities and Shareholders' Equity		$ (736)

XML 52 R41.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 144	$ (249)
Federal tax expense (benefit)	210	(229)
State tax expense (benefit)	(66)	$ (20)
Deferred income tax valuation allowance	10,818
Net deferred tax assets	378
Net operating loss carry-forward	$ 10,000

XML 53 R42.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2016 Hospital
Commitments and Contingencies Disclosure [Abstract]
Number of hospital facilities	4

XML 54 R43.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) $ in Thousands	Sep. 30, 2016 USD ($)
Long-Term Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	$ 7,637
Payments due in 2 years	51
Payments due in 3 years	47
Payments due in 4 years	49
Payments due in 5+ years	1,758
Contractual obligations, commitments and contingencies	9,542
Operating Leases [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	461
Payments due in 2 years	368
Payments due in 3 years	303
Payments due in 4 years	255
Payments due in 5+ years	74
Contractual obligations, commitments and contingencies	1,461
Interest on Outstanding Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	519
Payments due in 2 years	104
Payments due in 3 years	101
Payments due in 4 years	98
Payments due in 5+ years	746
Contractual obligations, commitments and contingencies	$ 1,568

XML 55 R44.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - Management [Member] $ in Thousands	3 Months Ended
	Sep. 30, 2016 USD ($) Law_Firm	Sep. 30, 2015 USD ($)	Jun. 30, 2016 USD ($)
Related Party Transaction [Line Items]
Legal services to these law firms	$ 197	$ 84
Amount payable to law firms	$ 168		$ 75
Number of law firms related to entities \| Law_Firm	2

XML 56 R45.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2016 Segment
Segment Reporting [Abstract]
Number of segments	2

XML 57 R46.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Segment Reporting Information [Line Items]
Net revenues from external customers	$ 13,046	$ 16,584
Operating profit (loss)	(953)	(1,166)
Depreciation and amortization	444	427
Assets	40,663	55,295	$ 44,105
Expenditures for property, plant and equipment	244	463
Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	5,357	8,795
Operating Segments [Member] \| Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	5,455	8,795
Operating profit (loss)	78	(498)
Depreciation and amortization	173	181
Assets	13,686	27,080
Expenditures for property, plant and equipment	54	35
Operating Segments [Member] \| Pharmacy Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	7,341	7,567
Operating profit (loss)	(192)	(79)
Depreciation and amortization	254	198
Assets	11,420	11,855
Expenditures for property, plant and equipment	189	428
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	250	222
Operating profit (loss)	(839)	(589)
Depreciation and amortization	17	48
Assets	15,557	16,360
Expenditures for property, plant and equipment	$ 1	$ 0

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&ULE57;CILP$/T5Q -OHL)8!N^4-&(?5E*VNR@2 M984I$D^LQ8WZC#) PH>K=K MW9BULU\V<6\V;0![ [C4(.D-DL' IBZRGIFXOB&)BIRS+A MTO\VV"DXUR2* M.5#!"',TZ;*W]R(!ZSRZ:R('<[ 8:#!@0$2*?5("NA('.#*'4P+',2(!V;Q$ MXD61&(+$2FR2>8+4(T@-06H)MMED&L:8!&SF15:>R,H1V4Z*K!R1[;S(VA-9 MCPEB,"GB8& \+Y)Y(IDCDDR*.!BXX-UL/)&-DPHX3[#U"+9??14@]JLC7I!- M%P07. H^52%P*):X"GT*^.5H_2H"B9/QE1MM8VNU!V56!\0+7@_PJPVXI91. MI]4!P=33B49]CF)^-?U?!"6[-=(VM.%VF#'/T/3)#WB1M^B*?R%^K1L1G)A4 MW=8TV@MC$BLOXB=5D)6:@L.!X(O4VTSMN9T+]B!9^QASPZPM_@-02P,$% M @ 6X%J2>;W"LYT @ 9@D !D !X;"]W;W)K&ULE5;;DMH@&'Z53!Y@$\C9B;NJP2VM2.MU>#_UOX#)&L0"(A$_*GRE6ML3P6\(^1"=;[NI M'XH8<(VW3$@@_KK@!:YKH<2=?RG1AZ<@ZNV;^DJFR\/?((H7I/Y9[=B11QOZ MW@[OT;EF[^3Z%:L<$B&X)3653V][IHPT-XKO->BS?U>M?%_[+WFH:&X"5 1X M)_25>$J(%"%Z$-)_$F)%B,$PT'$5A"Q%@0LP+! 8@DD_UN&U!)(M0@BD+B27*=:DE$8 MCL@SLUPRW07FSBEA8HIAD]PRR8U48N<:,##1B$P*RZ0P!(!SWA1:O4">#)N MT%[RH3$QH--&@>S)IT%>#0A(PMR%6IDHF(R)^*]-"AB%<:[ZA04:,5V!O>X! M-"2<"W>N0(ZTGQO9^P.(#"/GRIB#)UO$+(+SWW3HWW3#0SWN[Z:T#?8>1TN]7E86,ET M)27>_OOJRUZ2H4NZ%TN4W\P\DO,>;:W/NOW>'93JDQ]-?>R>5H>^/SVF:?=Z M4$W9?=$G=1R^V>NV*?MAV+ZEW:E5Y6X*:NH4"1%I4U;'U68]/?O:;M;ZO:^K MH_K:)MU[TY3M/UM5Z_/3"E:7!]^JMT,_/D@WZ_0:MZL:=>PJ?4Q:M7]:_0*/ MSU2,D GQ9Z7.G7&?C.1?M/X^#G[?/:W(R$'5ZK4?4Y3#Y4,5JJ['3$/EOY>D M/VN.@>;])?NOTW0'^B]EIPI=_U7M^L/ EJR2G=J7[W7_39]_4\L<^)CP5=?= M])F\OG>];BXAJZ0I?\S7ZCA=S_,W&5G"_ &X!. U -A_!M E@,8&L"6 .0'I M/)5I(9[+OMRL6WU.NE,YM@<\#O!V3#)D3H;9=]-P6M_YZ<>&4K%./\9$%F8[ M8W#"H ]16 CN@SR;$"FOD'3@Z"6*#E&,\TQDC M9PPA7E!A@E"*+$R%.5281<7+9(:(N0@C?KZ%B0*9Y1CFPATNW.#"P,N%&U6$ M%%XF)D;2"!["X2%,'NCE(8P://0.D]Q@POW[F)M; MQ*A@7BHF:CBL.(2Y ''=C9ALO'6V"^8B(B!>-A8*@!3/7 MH?*&[BT4XR*B8\ U5$"SS9EWVML%) -]OL!\C7Z;D&O08#DTB]EOUUB!W7M* M@.N'P"WUWUA_T^Y0QIQGX!H>B. I4(#E9C(G,8OBVAG(H,47("U-\ICV=CT( MLJ"%%Y!9]IP;7G6[D&LQD(<-NH#<:LDLII_0]0\D05\MT'2&C$#$V8>N,R $ M7;- L R1YR2BT*=?41@TQ )-,5.0$5N$KI:1!JVN6##+#DD1LW"NX)&%3:Q M]C]:P?4%M'R!Q9!U%8_B7G="5\LH(]P)33$_1$@972EC%O8FS.ZMXNH8\[ Q MH2GC!XDQ/_Q=%5,2-B9*[J_CJIA"A"]1L K1"'515\44P[9$314_ZU[->0B7P;2!U7NKH-:[?OQ5@[W[?RZ8Q[T M^G1Y>W-]A;3Y%U!+ P04 " !;@6I)0_&4#[M6=(^,4237EIU ,'*.#(5$2PBC*0HJZ/J@KL_;.ZXJ=)>EZ_,Z! M.%.*^+\&$S9N@CBX+7QTIU;JA;"NPHEWZ"CN1<=ZP/%Q$[S%ZVVI$0;PN\.C M<,9 9]\Q]JDG/P^;(-(1,,%[J160NESP%A.BA93QWZOFW5(3W?%-_;NI5J7? M(8&WC/SI#K)58:, '/ 1G8G\8.,/?"UAI07WC CS#_9G(1F]40) T9>]=KVY MCO9.#J\T/P%>"7 B3#Y^0G(E)'=":BJUR4Q=WY!$=<79",2 ],..UPK.M8A2 M!JH88:9FN^SJI4[2I HO6FB&:2P&&DP\(4*E[K6 &Q3+&R*F8W_#!2.39(_85(N3,J92>$U*=V#%JG?PB9T7G"*^

J)YK6^1=IJX&=,*_$#]UO0 [)E7[,9WGR)C$ M*E[TJHY6J[X*TX3@H]3#7(VY;91V(MEP:_O3MZ?^#U!+ P04 " !;@6I) M.OG$N*@! "Q P &0 'AL+W=ONZPLD*KN!9$S-)R?3[ 03.^R1+SH47W@_6%VA=T977<@G* M<%1$0[=/'K/=H?2( /C+8387,?'>CXBO/OG=[I/46P !C?4*S"TG> (AO)!K M_'_1_&SIB9?Q6?UGF-:Y/S(#3RC^\=8.SFR:D!8Z-@G[@O,O6$;8>,$&A0E? MTDS&HCQ3$B+96URY"NL<_VS+A?8U(5\(^4K(\V \-@HV?S#+ZDKC3,S(_-EE M.P?77L0I$^?-A#1,'ZNGNB@?*GKR0E>80\3D 9.M".K4OVR17["R"0!'[;XKO!@^7!U#&IR4 MC9NW5M?;^1C/Y!->5R/KX0_3/5>&'-&ZDPV'VB%:&PO=V]R:W-H965T>PXVYI)31UA'.=1PZHV7,[- MV'.WG(N3JJN6/W>!/#4-Z_ZN>"W.BQ#"R\!+M3^H?B!:SJ/KO&W5\%96H@TZ MOEN$7^!QA5D/,8A?%3]+IQWTQ:^%>.T[/[:+,.YKX#7?J)Z"Z<<;?^)UW3-I MY3^6]+]F/]%M7]B_F>7J\M=,\B=1_ZZVZJ"KC<-@RW?L5*L78R)0P:]CX\J]8\S\,_L]A.FYZ =@)>)^!0^"!DROS*%%O..W$. MY)'UFP>/&M[U))HYT+5)TS6K'T;?EDF&\^BM)QIA5@,AOV(BS3\I@IX( M&H+4BB3W"1*/(#$$B25([Q.D'D$ZJB ;+[,=ECE@"H,I\J2XKY)Y*ME()9]4 M&3"YP61P7R/W-/*11C&ID3L:*6$=A:=1C#1FDQJ%JU'>UYAY&K.11CFI,7,T MH' *^5"E]%1*5R6/)U5*1Z7,4KRO K&?HGBD0]A6N DB?-;CX,<,D.!R"[(; M1RK53R,D!)];4&Y?"6'OP \MI 2O6Y#5B0F'"_BQA8S@=W"#B\[+_5C'CR[D M!,^#&]Z"8@,_O5 03 ]N?H'F S_",,IP3@F.GT\H/^MZ]+.',<'U%G0Y=@GG M%?H!12"XWH+L:XTIZ[GY6"+!]8@C'<+NH9]B3 BN1S?%)2'$Z(<84X+I,1V9 MGG+%\$.,&<'U%C1\XR&[.94BY_)T9'O^DW7[JI7!6BA]#S-7L)T0BFNN^$%S M'?1U]]JI^4[US4*WN^$".'24.%[NL]=+]?(?4$L#!!0 ( %N!:DD]D'S4 M^ $ (,% 9 >&PO=V]R:W-H965TV$[=_7%T( H4U?L&=\SIDSQG;: MEMK M( 'EWGL-=J?$("S@5PV=',V1\7[F_,,$/XJ]YQL+0"%71H'HX09'H-0(Z<)_ M>LU'24,PT7!@1K8QT]]*&=G]=]I9%293BFQ&:8 X.$UI,,""P M5E\L$4Y+',(1/4KBI1+',28,UDN8TU1G]=Q(-.LUL@)1+Y \%XAG K$5B'N! MFLP:[=9VT7,<8S9Q,]]K&8^5A,?FT4?J[&/9LL.[\AJ:LS[+'X+=T=V!ATR6MN0" M/XFXU(U$9Z[T3;*7J.1<@;;FO^C^*_TB#@&%4IGI6L^%>R1;4]@"-O2FI[R'KGACVEMNY!P2)TR%; M99?"B^AZ%PJT*NG":X0";05J8J ]9(^K_7$=$!'P2\!DKV(2O)\07T/RHSED M>; $FH7%+A?SO $4@8AW_C/K/G>,A"OXXOZMSBM=W_B%IY0_A:-Z[W9/",- MM'R4[@6G[S"/L F"-4H;OZ0>K4-UH61$\;>T"AW7*?W9[F;:QP0V$]A"8,EX M:A1M?N6.5Z7!B=B!A[-;[3WJV*7E_0+.8Q$%BM1_\^5S@?6=P#H*K&<'['9(G5PFS#9B MV%T+>K6G"DP7KXXE-8[:I%6UATI5#^W9FY#$JFU2V]FT_[[^(%F8DH:]Q(:\ MF7D,S,.P/*OV9W>0L@]^UU73/2X.?7]\",-NJKLI%?VZ [U771_EG+2IT?%["X M='PK]X=^[ A7R_!JMRUKV72E:H)6[AX7'^#AB>$(F1#?2WGNC/=@)/^LU,^Q M\7G[N(A&#K*2FWYT40R/%YG+JAH]#9%_::>O,4=#\_WB_>,TW('^<]')7%4_ MRFU_&-A&BV K=\6IZK^I\R>IQR!&AQM5==-OL#EUO:HO)HN@+G[/S[*9GN?Y MGS329FX#U 9X-;C&<1LP;#?A_#;@VX,0@G(*IZ(O5LE7GH#L6X_* MAP'>CDX&S\$P^FYJ3OF=>U]6+&'+\&5T9&'6,P8G#%P1X>#=&0+M$<S-$5 M(#<12>*"/%E.Q'T2C(R33?9,CY/?=\") SXYX-J!L$DV\TAG3#(GBD4\=J%R M"Q6+U(.,(&2$1<899CUCX@GS+A/,R<4" <3Q?2XQX1(;7++(224VHG#.G4PL M#";W>22$1V+E)'$22 E Y:=#(/%U1TX,VJ U1VP$=W-$@GA0LG*K=0GDFAP@,^R@.FJKB7=6YA MWO$L]2!#E0<\I =,70&ZP5W(6*#48X\#JC[@(S]@*@NP.'5O$!8,DRB-/ A1 M;0$?<8'46CAN-B:&^2P:JBY@R@OS&0U2><$WRPM2>4$?>4%3.!+&P9D2&R5B MC]T*J;P@>E22!EWVYPS=="R4CU(A52ID]TM)8_2RO+%:+!#XE#52R4/N44IH MBAD 1R?GG,!2X;%^D8H>"H]20F%I2.:F8X(X^F2'BA[&5C'Y?(]3K<+DS<5$ MU053GV*ROEW$C1FR0.CQ[8%47S#S*:7,+)*4W9@@"R52CUIB5*M8=+^6-.:R M+3FY6!CNL588E3P&'I7$3#$#(6Y\4MFPF,4>,LZHZ#'TJ"0-2LAYTR)C0BB1 MT#@!U[+=3U<)7;!1IZ:?CY#7WNMUQ8?IMH+TK^$AGR\=7MVLEL=B+[\4[;YL MNN!9]C_4^$$6VVNCDKM^?$V&]W:^>I@;O3I>;E*NUSFK MOU!+ P04 " !;@6I)$'PJ=YHL "SO % 'AL+W-H87)E9%-T&UL[7W;;MQ(EN!SQU<$"NH=&4NI\G[Q5!>0MN2RNF5;[931VV@L%A23 MF6*;26;S8EF#?JA_V'W8!69>YM/J2^9<(H+!9)"9+).LZU?P#^SS??Y+@O]57X?AL4V_G[0ZTV^W_I1\MV//^31CS\4/UZD0;D- MDT+ZR4I>)D54/,JKA&>(TD2>R?S>S\+\A^^+'W_X'M_A]X;R39H4]SF\LPI7 M^T^7X>Y<#GN>'/3ZD_V';]-/Y[+?\M#L9^'>SU\6=WF1^4'QWUO?O'WQO]I^N_3AO3&/6N FS*,4-KN2%7S3&Z?.+W_RF\Y"O MHCSP8_GGT,_D*_BQ >;]D6I=Y]@_]O=_NY?&C4TN_[S_DP+X M^W 3(91AW;?^MGFZ#V^OK][^0;Z^7%S?OI;+/R]O+]\LY=7;ERWSO8039+#[ M*\"5S_(/X>/^N)=EENW#HPVV9V>]R=FPU[+4JR@.,_D2WMND66.=Y=:/\?G[ M<)=F!8+F9;K=^4ECH-YXNMT"TBV+-/CHR251@GQ7%GD!Y *O-\Z1P@F3/%S! MFTF>QM$*-K*2+_S83X(0)@ RS(&F/BPOY.G),WDBHT3>WJ=E#O,U+O3W9=). M11IDBSR'.9\W'OOY/=%T@'\)_U9&G_P8QC<6>1\&(3R[BT/<6!(6^P.NDD_P MG@.8%^$ZA#VLX Q!N@UEX7^6/NZF;:OT,)?W8;R20-$RAQWMC[W)PIT?K63X M>8> I".DQ3W<&;_=0/&T (0):BLTYP3&F!6/GMS%OF)U")$=4I8G_4(&:=[8 M]768Y](/@/[*F&YQ%0(O#2+B0T]:P@W7MVD2=-_A50)HMHG@:C3HG!/]E*:K MARANT+>UP#&0?T=03O9?<@/\\+!WMXMKN5@N+V^7;?@01_Y=%$=%%#;/O@@" M%'>YW/F/B)QM M6B2I.1XBF*,L$#LEJ"D%.'V#B"L90R] M T] \(2M@F>Q6D4%7Q]RZC.08(&_BP#Z3=%2@*J)V.MG"6RA<9:%Q5V9R0-B M 9CO =>C3R'<9MYRS\< G%G0]=7BQ=7UU>W5Y5(NWE[(Y>O%^\O7[ZXO+M\O MX1L6'1A_U*3ID_4D R5BYN] HI*PS169VJAQ MJ5!*GEX#DCRS="J%X+9BY1U0M&QS9=S"VZL;;+\KM6-0*[,0E*82MG$* AL/ M$Z0)O5/"K8,.FCX@)N7/G$H'L,A/$7)(8IAW_HK8,<'D=>C'Q7T )Y2O_$ + MDF6XP9TU># LK3?2O(&\8+A>MH@6'(%+;D"]R"5<4M/* WK((L(??Q/R;'=A M$JXCIP[6=J;E#K6J&(3 #5S=U@\>VPZT+'>[V,'0;\HLN/<1G9!!1T%S!$N2 MU-Q/FSQ]KX5"',)\>EA3$E::(//,+9H3_^14#2NDN':P,]X8XY@G3]5E/&OH M0S\!)Y5(7* J(-#<6I<>%7[&!.NO*1ICV>0T8B8NO8.S=HSQ5,'WF!- AH"H= MZ !0_4>%+\F>:=<"D2=-\-3#:QQR;=WU$K"(C*3(Z2KDOSW#UXUGAOYRV>Z9 M:1TH7X2;*$GHY&OE$CS^9?2K=;]V@PZ84W8,A:MGB$DNWP3)CG96WP0*LC*B M_1NTI)+"+2ZSC9\H4>I9#$2+6OO=NC)M\9<.CI 6H>R?RU]^_I_.[8C;^Q"M M;G8+(HC+Q"^!IIB;N?B:V8&P=N"S:N,VL9 T0:; _[,PE%MTI,L=W47I+S__\_+RY2\__\LS'./AP?(R MN/?D*@7+G+ \+EB'7H;P>(&FHMC>H[G MQ7,(W->')#("@^"XV )T I]V\]-B<8/;.0=!$8K W$E@WTG-@@5UDPTW"H/H M'1/4BOLHAVT#+D=;N09]&K8(FB2#%XQ+) !F6+@OC0AK<^.Y=>,%C('_X ;D M'1A3JQ0VOP,F&'1Z7$ 91,@YA;M?J!(P\/(BB%I&('.1L MC!J[Q! 10@- ^-C^"(GL0]OP%68/TH) ';" 7F5R'24?E=$BEX\YC 1E M#'C$N2#$X@%PFQX0Y#\_A/IO:9GA7P7_-=<_E_@WJ8@'_JV<]X@-8I$D:%NQ M9Q_Y_2L ,!+ 'PRYK3FZ$C1!2:S&IIX<*H8?C0G![S'B9JT> Y'H!'I+DJ8 M#XFMGX"6Q!YE?/2$FP#[Z3X*[@5:=8;;>#6T\5=_+?-"C<:;B%C@I@F0#^!4 M@M@4BPP).L,'M1<28.5Y[F>/Z,W<,;>3:S_*X&4&C,:HG79(,%+F9 M#30UPXI XPCP;(2#!UZR.)[@"60[PP-P(/GHW4>P6[48:M< \$:CVAOZS\B M/J.1$1"AJF7AO$!/-02 )X Z@MU.F@/PELX;@JO,HP0M\W8[A.3*@.2*= P7 MKM\T?:0/:$:I 4#^A UT_!WK6QF!\[ZR_;69*Y!H0<%#LV_K9Q]#HD+9X*'G MTI#:_ZF6$B#^D*NDB*6*,<%>8+G[:$<_/*1F,*Q)-GG^'*CR7^FJ.YT1N2?X M'/5%^.T%R)"[/%I%B),\C( 6"<8:T@DR=GH+(9S(AF=W2%-^ '8/9*6O$]S M\CIJZE'D0N_U9SA<_G3SP6/[7$XF]$L"W(1X/"@IYX>V(O56A ^,I->< * 0 MY?;[?IRGZG6S/W%71C&%88U?(6<"0I\!*S&$O&9<&@3E+F+V#P,%<(D,W=./ M&(+R,_9< R7#08%=K%%L$6^Q$$0C#I_Q%NXQQU=1-)GM1@;58,=B&R)EQ687 MFBL1'M*N5[AFRX+"8.H!J,H@1DP0&CJR!AU?ZFVDL$H05D\5+A4ZUA$_BDR9 MDC20?/2XP30)CX4*LOA6WY-!JSJ-K$$>58P-G7FHV3-6D[\[ECL]$RRW*@-V MLPE-LIY6 RKHH@Y3!JS_R*S$2+DBYG^D>:\28/9%J9WN>GH](P^J3M(<0!O M01$!(!6Q?82I):D4'PP_*PEKH&F60V!:2+6N M6%^-M(B!,"]F=T"&%J<6L +6P7W9KP#L '4!/V$WJ!X259"?CT6K4G<$R7^2 M"CBY-2DA:+6=BH6QHXYH&&6[^(3K%8]J?)%F)#9\%=EA.H<%SM1&4'G6^@AL M2M"F.% ^)R%19F1VS$B1X!2AS'W #8<%CPG*=$:JJ3S[D!D@ES&^*4:!_OP M=#!)\C6QOR=!UXJ'JLLGGY1T(/YH>P>\F)^SP$!IO\K*#2^N<5Q3 1])XM'3 M,A>OPA5:'S24=%@DUTWF;W-Y&IYOSCWYAB;(. >!_Q&MGK&7^Q$8'EC4^!8% MA%$IRX"A$X/5Z%CE+E0/T[N_AN@U )DLK#MER4&\AN^64,\ J-S!SE;J2BW MY *N2BL "J.BABTL<@MK/;2H MPF0#^C&P^-6G*$>$0P&6HQZ+7!T,OQ#QB7US+!WA(?(J[4LC:FDR.4V6#G#B MLB C_0WHG,S2@=H0_+BVP@-BOA%[B1&8>8C:=IL8JH,1YR_)] 1^AQ+0\@"" M)HY0LH@SK]SVI(;[2'YK?7O"3@P@](7G)2; V'H"<3+-F2BSAR=$LUP\T-;Q M[4?R=]E8AE+$J37B]3/2-9?@,W S#'-@/VM MK?<\:59";XC 9+G<#^K+:(M]I=\W/W@\AFT79+UP7X+NTUP:Y9U4N(9L6X=: M$,)KN"L*J-RA%PN1GR0Q!G$+\@2P)T'-4O.-N&QW3W09ZYYA [6)ZN(.E$ 3 M?B8]#)6]-(Z9W?$^$3WK=K]PV?W2LOM%N]U_CK^2"K[* ""(3WGQ&(>HLZ'A MN U]5I2UBG1$T99L)SPS#QN,U147QOCQ3"R2E*3=+3L06#\H G=51XK[:E"GHT&V\JV M5D@ZK8B^ L6_X?B(R?4+LY2EVIU[ J_\R-#2D<-H&Q=$BH!V/P&J[@XZ:8=L M3+?,*!:5,\T&%8PN\[SR02$9H+Q+'PA:&;F'$&"Y:/'_&^G5XEIT.O^0;Z%> M#UH!WCB[1BQ/+;MCF#* 2F(20NA[W%F^YW/Q7CDS]'3- ]H^-OL PCX F3HT M;P6(=8I9!R1=T01XCAPC#&M9W,(X803F+I,3!CW. J,9[U4BP7-A@EH&B^6) M''C]7A_^''JSV4QPQ'0)PL*, ;5J,!S)9VA)BQ/9]V:3*8V?P_@J&!E3-HECQ!V;'CJ#483V1/[Z2NNJ7FLFKDKA [ GP!H M![-A8UX2_6V(?B)'WF Z).@-Q[!(<\-.@#((ES8(+RT0*@V1]#$RG1,=\\5] M1Y2>P"=P> 5S]@>*C@ (*B>H"*)8B<&V?$!EP,\5AN=/PFR3 D'9+H"6"(W^ M1%QJ#V)EW"C5[910":]D825]T.F(]I6Y02G%RNXV8TJ@T=-M*N"=7<9Q M]%'O0"'X'&V!SD#_.!EY\UZ/50.R=-BAJ*T47R8EH:UE MIE2&."SVB#INB7I]'*&/D*W5**]\X(@"Z',3H.I>@%7"R-+7D0Q<&*V%RC(! MS16SO?#R3X"M RLT<@P###%:;>N(9*B^D]?Z3I9T!!7^::"F.":QLH%,G-UY M"$G&C"1V8BCZ4_AE<0M\\X5*3<,[+D*.(HUL*EL%I*9]+Y_((%,]*$!EG",DM4Y*2 ML^*U*H/0FC19@R[+Y0V"K2%?F#MS:^, M!"3## 4EN[C)LM$A%L'A=@_-&!_5_#5E2T>(APRRX6Q03;@*SP55(IV]\'-E MLP Q<1#Y5:LH[TJJSJM6U[,RO"J"1[%O7!"=/,K!NL2L,@+2CPF'2T)092 MYEJ(O8A] - R !: -@Z]A9*9X+\%&,;*?2!(;9ARJCWN"TYJLNX;R['O$!< ML/6%]@QP91B8);0,8;8E4+ON0AQ0:[23@W8Y&E=;$UU;ZXT5PT.S'9$<^,C> MKL0Q&#)N,&&E_H,90#AB8L2F3L>J(^LJ,3O Q2?,Q0^M)JPI;;]?7=I'E$JA M<+I*R59LDHTTC*!R),;XB:U(T>J\.F!FED1\VE(\6JA0/+GVMCP.I;'*&(FR MU9E=-D1GV &IF)0-T;9QE%T6WU..%)L3B\P"*WJ.,9,G8%\=G _(R!V*UT6! M8HW:,AQ0[;M5:5)@Q&0P4F *X'2%3L/4IX$=?@I5RLH&_YK@" Q7::\Z^LG0 M[':ZU2U?N0-LZE7EVA98P PLG%2&U$H7RRD_Z/6;=SG'EBKAIP-_HCG\YH:' M6SO0KOTHR4$\9.S;JK*58O3K@*!*.D$&/R"#@NL! 8=PB6+RV608%=<94&7!<)"WOBG49F[E)1[3V M5\E'9!)P01EEOQE63'=@HYQ!LXH-HQ<3D",& ..6Z%VFH PQEDYZ;U$BA7R; M]"6,ET8=JB4?S^V@<>A@CN0O]!N#\1KPL9] M<_,+C=@G6:F=(9KG%46A&Z8W'));9=R;"T-= V\TA[F\^6 B\3K,XP^]/MS M.1F-Q1O*7,),49CBO_C;W3]*796@W.H@)GLX1V^@_ &#@1P.+=BP]Z)>M]+$ MN+$WG/?DW!N#!+TY,/84C@%V]K2/CICN$)7MG<(UQE,Y\Z;SL6C$K&HCI]YP MU(?_CB=3=2KS:#B:P1$'@FO-:F^AB\#KC2;D)O#&LY'0!I3!:J6W-%:ON^6X M(D'4ZH*JG"U6ACH*@9!(&RM$N;6 3]D6VO]B"0&K_$5$FHD]N1Y+U&L=T-T$ MZFFYW:*5;2>"V@S-%J(<#3!.FQJM"-N],&';T26(#U17P25-O,E\!G].O?YX M*KBF^P!C/)W.!XA[\WD?<.^&!9SS"%0O Y./P8:?T&+]R800HO*VXC&!>3)< M%&KXG#?^:/B;O2/1W)%F,8=#M4ZT:.=0+;:!:.-0]?&"C5+;E:*7)LH1VJZG MDE*0G,KI@) :C,C[A3XP@+/0XM!2V!0&DU#260E9Y81VUB(!TX!+ZP]&HBT0 M,>I-Q2\__R_ZTV#4 ZA.H%"@"\>4"N$^/H6D_)Q.)H00$W+]38<]0 OK: X8 MGL#\ SP@\#O O?G@*%B.GP[+,3EQYQ-:;#8F7!R.IE\+GE-8 !@A+-;KM<,4 MGO89JO-Q[WBH]KUYGYA\?T)_@.R:3@Z EL\[G6&H :N9\;R#0:-F4[=$()JP MVB@LW%5SG:,I A6GJ H>LEZFY\ 2NF<3=B+FQAX:-;H]<&Z8E3IYD$<'RJGDSG^7PR]V7@FZ;_"KB^O>>L! M]_ISC@EYA'U*U-N0065J,NGQGZ!-U";0;OP'H*F3X43Y2B9?):+1L+VKW@T7 MSK8,=\51..KN94"(.R.SN[Z.J'>#T)A2I0H;7#D"+3CJ_?YB 8H"&$XHC\?3 M,?T)\EDL7]_<5$^!,8QZ^%_@)E6^H'Q+&0WX8-R;P0..J'&AKNVOJPRYP50. MM18':N<(&!G<]VS&>@ 8$GRE(>M5Y+$BSA-0<30HGW-F^,B5Z)6@V77D%#0+ M9F-3;S1%5,+@YK3/B#.?SO?/CMOCG_Z49A^I!Q$?1>!CX**B2A,P+U$JDZ3+ M .@#&\183,ZE"H1E,9DG6E<3JLS&-ZR%HUQ8A(-I)]BXP4Y',.O1]/OZM!P:].(U@KLEO0>">]W[KEK#/G+N/D6L MOXZ19Z4>/+-4D=8*$D$ M[7>Q*7URQM6\<1_.E^= 2"9A&\N8-AEFE:"%[LGWF.@K+D "QRGOYX6588J] MLF!%T!EOV(%R;J'%'N(HO(+WMJS5:>\5Z]XHY=/X$SG*87[2ET$+B KE^ )> M1L5&P-9(LQA8W GY6Y*B59^$#^0.V^L.0A:]]E,F:E06LUQ&9*9\(-402;O@? MJ*3 --H.,_\T-3G5*N:9V (G*A4@?1U"!7ARYA/#6E5VJ5.28V^[@S%$R+X@ MC8HNJ-ZX"0[^XQ.$1#%&R+%*.7SKDM"#WH+IKQ\ M<75[L>"$=,R'J>(/1>,BZ.9;1%B-WWOJ184Y7%8&9XR(LYK:*GOGTNQ<-'?> MOG%^#E?T-A7;=!6MJ3((0S 9K [7F!EQ[-AXHA[5A15J)=9V32E@>J=:V7!= MIPDY]VVKR=]W=$4)[CA<<2;86IZPU'/6AO9[$\K[.B&)J,;4RQ@;>3T.G- 6 M?4OR4JT2TAB6($!7[):T7-+(XE0Z%<6N9 N,21L SKL'.G/3,?*DC E)>[0- MYU7Y"6A28$B=DD791:@J(&MX8B3:*Q33:J4PE+1@[ MM-SJ[-2EHAB,WJ.ASVF8Y!NW(^WDT:\<*+ZI_#Z75^HPF'8(.@4Y:YU32S-U M;3ID3WAVE(CNXZ8NBK1WQY+,0#)8Z@CR-K'[%/EA UC MVBZ%8I5Z8_P5-AY[[ E>^U%["O.^$0LE11B1*L M1'F6!F55M.TK17)?*1)'*T6R32D2#:6H>265QJ!3 :J$S4J.$QXHHTM?R&'A MVTC2=TLQ)5"M@#Z=O;[-1565P*H!/=["\23%MW#G>&3.,\^P9DNI%RIZ$7(? M!TS?L!.TZB 1^FZ?1%W\^CV&V#L2H+A6@OA%/07*U'U2),D@E>':\"0F!J8S M;?%?)FN>VG]B942Y8\8A,"^*\N>C0I?(H#\52XX;]J%8+#^037TVI#3R9802 M:?VH8_+[[2/(TKW2AA]UQ0*5_P@?+JG2$>;(8W6#'Q15,8&_4GD'B-UF.S)J M!@QK\EW4PES'"/#G8I'+114U('F^H'2DEB:J>ZB-)NITBD[8TSFET<(_)S/A M:JJ* 8^I-Z/AE MT)^K5Q9ZW&CDS4:T#S+-^1=,9CRF*2B,GGF]_H"S7OD@9+F+UEZ:")>>-R9? MKGD'?NF-^_M.$HR\]:=TAOY\JD!*3H#V]I3LTB07KGEIY(TG8_72]1[3<:>X M=<"ET:Y2)1/?=O3JPB2NXQV?3I":B[4J==V2-( YY, M.'(KJ+Y%)SFS7#9SJM\Y2W$TQSD'JO*KS8E&BHD*&K8F5,41 M==VH1->6*MN#:AA]7>CJ8]4F9\Y0+1:;V]*8VR$E,,*?LQ MI!X5(!_ F,1$N5P=OR'"'^Y#8D3ZG,)*_M.RA9,3T(^!Y@0$D%OP#Q9T5J-'RK'A$9Q%H&6+4+D8SC0<-A!7968DD8^]#0."$F(J M7,\CIV$ ]CW@@7552=WWH>6158L?*2V)50%8F](SU.'->OLXH6!E3"B3Y(37 MBH-==I,Z(KS.,5VB3SNI7&_:I%FQ=:>:+H=;K.T#H0J(##OA>@*E+E4N%E4Z MII0%4_1FHJE\QYP5 ]NG^!;LAH]O$EA:SLNXP8<6B.#5-5C_3" Y(TT0 03@!8;8 4=2PX4HAXZ[F:2P&CT4RF%F!T,@KB^CUOUI\)?3[V M .UO1>:I20#..$& HE"&HEV-IVGZX73F-G7@*/P44Y/,BI48=LX864+!GM7* MV;1Z-+%6JSO(9.;+ ILR6NGS [P$P.ML,.V=RS_9'1_2.A\"#=*N #>,4QQ@ MG#4>OD>LZEI%"U)1,Z/Z-NA>-V33(Q?.([A?%#2(W]06DK)ZS=IX98B"IK:= M*EI]3D1#E_R6NY2AR5":,?I]N*(X3SU&X.92 F?>P M)2B[#>4O6N MS.9=1W?Q"-=5F+)P7:19Z49-0D<#3_U4V5P'J5]JZJ=$_5?-@@-=W.ZY^5@] M4?_>7\F],J(^9Z^C0\!.Q[0T%;Q;5BC.E$:16XH9GH***Q(MT]EA9M4[X,FM M$(I&/).D1K]G?CHF@47)HVJYC['B7/93V3P.JZ>\U[NJKV M8W<29F],GPL-*3> BB0YGA M^)$'\;&/J4/M[XN%J9O9KS#::[9"?B64=7;;&9%C!]J"6I21*Q$O--++?Y 8$@5\)+^B;E.EVWOE594$, 25RM1LBJ*L^15[##<9RH90D!XXG[(] M/AL1RXGA45R;E,-19B.UTE?QA:8W.B9JG2EM6!E'F^B*E+5_+Z/NPP/=\:0/ MJ,FAO$:MLE4GHCX44SNSH#,W6&3E(K _A7;7WB=?Y5Y5G[GZDJ2@_@!Q\M#: MX@.)191QM^DN"N3;]%P.9@"/QBX\BSGI;H+4]%([RI5F5A6,8[P*607H73F9 M5&5AJG6XG9VEX]E)QY$MV]A,RF5E@&74#I>"\X^D%@7W46@G2*_"@!.O,2*9 M461%_W0&/Y&$QRX6:!T)?++BIH /5+0+;#%@BSL'C28P3)B4,0ZG6@HI]UYK MVT%MN;UFBK5D0IX@_!P&I>J/B<[XS'+^5F1?>S$/$RQO+2_7V6]=WPZ DTAW4.$9*#F%6@$"$I$X)+1E0J<*Z\#*JJ[G6KF MJD=4^X2++^[3E2BMOB@:-APR,@4$%@DYLA1$O1&U[VYE3;9!HI@T9?D+HRE4 MZ *:D!9.%N*8]%&N1%/@D%QVN=:@1EW 9F/,0&P\_,@LC\=PO0C^!,SF(6* M:L!2D]D$\Q-'@YX$"38>P_.>-YD,Q1/;^N/<>SLEF(UG;]9#X,W@ M%F'UX:0GQV-O,!\_%7C#,4P\DSU0.H>-N$E; OSI+97$-;[PL0SNPU7)-L21 M#92^=0#ZU@'H/ZX#D.M[-I4V=J-ZV%RZOXK$F9+?^OUT]_OY-87U[8RFRDUX MW_+!KV^%K-\*63L+6=MPZFJOEM.!F&VO_O]+YK1+SJU1B M=L$? _57E,U[5<_FE0MG-N]1;O1O6<3?LHC_W\TB[H[%'^,3.S:&?B@GX%M( M_3]92/U04+$=>XSF8%X[BA-_"T%]"T%]"T%]"T']IP]!.;XC*<^L;I(UAGIZ M05^D<[KO=\H5O>'S[^WL2R0Y>'YNL**S84]&84M.VF M6@#JJ8\'LN=E@L M/84F%!EU2K(CQHQ;QER$P;G^*,9( [BE--9T1?7J'Z[@L&UUY"H;G8*N>Y^_ M\E12*MEH+1#LDJLWM:_[N3ZP4G&]"F,(@?XNVT[8@7JF?"\1C=F1!AL_WC MCGZT?+A0&;+JNQKII_.96_:(E7YXSSFVSQ\)4KU &T<$?OR$UVU10-+6X'IP."J -I\ MJPBAUO*QH ;+LIQS_Z!=B/L-()H5M7WG68K0)O3E;PAR0%5TY*K_2#LC:-;$GSA2M?OU,E!4$R/H5 M]G0XG>A7K\$3MDUSM('#TR@.]A50VL+H(])_GH[IOR^32B5K"(6G9_@T%(\C M$GP:P#Z4X?-UX'DX_^?IX'QAW,XJL-<*TNX+H:9^ZWU92?_(6#^2J6 W*GXQGYLTN87-P?4?^S%,WL?!"SOI9^[&KU?B#'I\;@]_-_GKK^J_#N'&,( M3KN%I@05I,A*AE8'HA^1FN,4G0<2"[>%G[09ISH!?QG*0 MZEX.4ZO"HP8T#)1:CE.K$;>?[W3LP(/98$?V@Z?'SXY"ZQ: 5 C75,#B<>>^(WOW%-3C"(*O0UO6:Y4]3^<-WJOD$B M;4U6/9GOLM!O3H3]4(^>Y5";^Z>T:MUK$;D!D;L)D[(A,*ZPBZIIFLZQA6JUEV&QUBJS6N?AS; M= N"H\7TNZ P08,&GQNT,*Z!BZ['+N9T>RS-N?G,?DOHYIJ.C1SEWM3G;N'P M^Q>S+Q^/NYLC/9D8V^FUQ$T7NPP(GNBGUTA!,U[Q3.6$H5L0<'=_W,P%)CTS M0: Y]XV[F;CJ-][T4AB%++Z4IUT7$^&EGUGU'9_U, M@/>'#8\; M-CINF$Z+=CE+GYZDWHQS[65]MU-^>S9X1X"@M7W9,R- M:__A?[R*LFU7R* MTZ/U )W8=7VH!YG#/81A3*N!5^M0*_'/=#2SFI5B)))D MR-]EV[D/ILI_E>S/]GWKK,TOV)_/AO4$L! A0# M% @ 6H%J20$JKH'8 0 ]QP !, ( ! %M#;VYT M96YT7U1Y<&5S72YX;6Q02P$"% ,4 " !:@6I)2'4%[L4 K @ "P M @ $) @ 7W)E;',O+G)E;'-02P$"% ,4 " !:@6I)>AY= MXL4! !G' &@ @ 'W @ >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " !:@6I)+D62%1(# !.# $ M @ 'T! 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( %J!:DDGAOAA M/0$ &D# 1 " 30( !D;V-0&UL4$L! A0#% @ 6H%J22L6QE&PO=V]R:V)O;VLN M>&UL4$L! A0#% @ 6H%J2; &\DY/ @ \0< !@ ( ! MJQ8 'AL+W=O(QPR 0 !,9 8 " 3 9 !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ M6H%J26&3?1%)! U!4 !@ ( !1B 'AL+W=O&PO=V]R M:W-H965T&UL4$L! A0#% @ 6H%J2:6G9-V< 0 L0, M !@ ( !N"D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6H%J2<&1_0BB 0 KP, !D ( ! M-2\ 'AL+W=O&PO=V]R:W-H965T(R !X;"]W;W)K&UL4$L! A0#% M @ 6H%J2:S[T-R@ 0 L0, !D ( !N#0 'AL+W=O**$! "Q P &0 M@ $2/ >&PO=V]R:W-H965TH] !X;"]W;W)K&UL4$L! A0#% @ 6H%J2?CDR8^^ 0 >P0 !D M ( !SC\ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 6H%J2:J+@>.B 0 L0, !D ( !DD4 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M6H%J22RP$A+\ @ U@T !D ( !ODL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6H%J2<;3CXS- 0 M[00 !D ( !L%, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%J21G+;JWV 0 O 4 !D M ( !=%L 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 6X%J216+X4Y9 @ $@D !D ( !#V, 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%J M2=3G=]6? @ B H !D ( !6VH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%J25PMH@BP P 3A( M !D ( !0W( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 6X%J24K[J JE @ 8 L !D M ( !9WH 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 6X%J2&PO XML 59 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 106 184 1 false 39 0 false 10 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.sunlinkhealth.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Disclosure - Basis of Presentation Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation Notes 6 false false R7.htm 108 - Disclosure - Business Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Business Operations Notes 7 false false R8.htm 109 - Disclosure - Discontinued Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Discontinued Operations Notes 8 false false R9.htm 110 - Disclosure - Assets held for sale Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsAssetsHeldForSaleDisclosureTextBlock Assets held for sale Notes 9 false false R10.htm 111 - Disclosure - Shareholders' Equity Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Shareholders' Equity Notes 10 false false R11.htm 112 - Disclosure - Revenue Recognition and Accounts Receivables Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlock Revenue Recognition and Accounts Receivables Notes 11 false false R12.htm 113 - Disclosure - Goodwill and Intangible Assets Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock Goodwill and Intangible Assets Notes 12 false false R13.htm 114 - Disclosure - Long-Term Debt Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Long-Term Debt Notes 13 false false R14.htm 115 - Disclosure - Income Taxes Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 14 false false R15.htm 116 - Disclosure - Commitments and Contingencies Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 15 false false R16.htm 117 - Disclosure - Related Party Transactions Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 16 false false R17.htm 118 - Disclosure - Financial Information by Segment Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Financial Information by Segment Notes 17 false false R18.htm 119 - Disclosure - Discontinued Operations (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlockTables Discontinued Operations (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock 18 false false R19.htm 120 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlockTables Revenue Recognition and Accounts Receivables (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRevenueAndAccountsReceivableTextBlock 19 false false R20.htm 121 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables Goodwill and Intangible Assets (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock 20 false false R21.htm 122 - Disclosure - Long-Term Debt (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables Long-Term Debt (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock 21 false false R22.htm 123 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables Commitments and Contingencies (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Financial Information by Segment (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Financial Information by Segment (Tables) Tables http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Business Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureBusinessOperationsAdditionalInformation Business Operations - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperations Discontinued Operations - Schedule of Discontinued Operations (Detail) Details 25 false false R26.htm 127 - Disclosure - Discontinued Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformation Discontinued Operations - Additional Information (Detail) Details 26 false false R27.htm 128 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsComponentsOfPensionExpense Discontinued Operations - Components of Pension Expense (Detail) Details 27 false false R28.htm 129 - Disclosure - Assets Held for Sale - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureAssetsHeldForSaleAdditionalInformation Assets Held for Sale - Additional Information (Detail) Details 28 false false R29.htm 130 - Disclosure - Shareholders' Equity - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation Shareholders' Equity - Additional Information (Detail) Details 29 false false R30.htm 131 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesSummaryOfRevenues Revenue Recognition and Accounts Receivables - Summary of Revenues (Detail) Details 30 false false R31.htm 132 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivableSummaryInformationForAccountsReceivable Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) Details 31 false false R32.htm 133 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivableSummaryOfAllowanceForDoubtfulAccounts Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) Details 32 false false R33.htm 134 - Disclosure - Goodwill and Intangible Assets - Goodwill (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsGoodwill Goodwill and Intangible Assets - Goodwill (Detail) Details 33 false false R34.htm 135 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssets Goodwill and Intangible Assets - Intangible Assets (Detail) Details 34 false false R35.htm 136 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation Goodwill and Intangible Assets - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtSummaryOfLongTermDebt Long-Term Debt - Summary of Long-Term Debt (Detail) Details 36 false false R37.htm 138 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtTraceRDALoanAndTraceWorkingCapitalLoanAdditionalInformation Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) Details http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables 37 false false R38.htm 139 - Disclosure - Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtSHPPRDALoanAdditionalInformation Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) Details http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables 38 false false R39.htm 140 - Disclosure - Long-Term Debt (Carmichael Notes) - Additional Information (Detail) Notes http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtCarmichaelNotesAdditionalInformation Long-Term Debt (Carmichael Notes) - Additional Information (Detail) Details http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables 39 false false R40.htm 141 - Disclosure - Long-Term Debt - Summary of Line Items Impacted by the Adoption of ASU 2015-3 (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtSummaryOfLineItemsImpactedByTheAdoptionOfASU20153 Long-Term Debt - Summary of Line Items Impacted by the Adoption of ASU 2015-3 (Detail) Details 40 false false R41.htm 142 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 41 false false R42.htm 143 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 42 false false R43.htm 144 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfContractualObligationsCommitmentsAndContingencies Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) Details 43 false false R44.htm 145 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 44 false false R45.htm 146 - Disclosure - Financial Information by Segment - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentAdditionalInformation Financial Information by Segment - Additional Information (Detail) Details 45 false false R46.htm 147 - Disclosure - Financial Information by Segment - Segment Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentSegmentInformation Financial Information by Segment - Segment Information (Detail) Details 46 false false All Reports Book All Reports ssy-20160930.xml ssy-20160930.xsd ssy-20160930_cal.xml ssy-20160930_def.xml ssy-20160930_lab.xml ssy-20160930_pre.xml true true ZIP 64 0001193125-16-765892-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-765892-xbrl.zip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end